<!DOCTYPE html><html><head><meta content="width=device-width, initial-scale=1, shrink-to-fit=no" name="viewport" /><meta content="text/html; charset=UTF-8" http-equiv="Content-Type" /><meta content="fdhmwDBTGwNPe0lKcJVly7AToLfZYvJ-mtjFAPTMZGs" name="google-site-verification" /><meta content="296E0FF6379AE64A0D18C39BB40ECD6E" name="msvalidate.01" /><meta content="DB01259" name="dc.identifier" /><meta content="Lapatinib" name="dc.title" /><meta content="Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding." name="description" /><link href="https://www.drugbank.ca/drugs/DB01259" rel="canonical" /><title>Lapatinib - DrugBank</title><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-57x57-precomposed.png" sizes="57x57" /><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-60x60-precomposed.png" sizes="60x60" /><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-72x72-precomposed.png" sizes="72x72" /><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-76x76-precomposed.png" sizes="76x76" /><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-114x114-precomposed.png" sizes="114x114" /><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-120x120-precomposed.png" sizes="120x120" /><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-144x144-precomposed.png" sizes="144x144" /><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-152x152-precomposed.png" sizes="152x152" /><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-180x180-precomposed.png" sizes="180x180" /><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon-precomposed.png" sizes="57x57" /><link rel="apple-touch-icon" type="image/x-icon" href="/favicons/apple-touch-icon.png" sizes="57x57" /><link rel="icon" type="image/png" href="/favicons/favicon-96x96.png" sizes="96x96" /><link rel="icon" type="image/png" href="/favicons/favicon-32x32.png" sizes="32x32" /><link rel="icon" type="image/png" href="/favicons/favicon-16x16.png" sizes="16x16" /><link rel="icon" type="image/png" href="/favicons/favicon.png" sizes="16x16" /><link rel="shortcut icon" type="image/x-icon" href="/favicons/favicon.ico" /><meta content="#da532c" name="msapplication-TileColor" /><meta content="/favicons/mstile-144x144.png" name="msapplication-TileImage" /><meta content="#ffffff" name="theme-color" /><meta content="DrugBank" name="application-name" /><link rel="stylesheet" media="all" href="/assets/public-00a92ba10a1541e1942963fb53d210fb40b3219c1ab19bdeb8d842d14642b01c.css" data-turbolinks-track="true" /><script src="/assets/public-2b363d994c1aa223bf4c884cb2bbefc4e1834eadc952fe6ff2b6611da9e7dee8.js" media="all" data-turbolinks-track="true"></script><script>GoogleAnalytics.load();</script><script>(function(h,o,t,j,a,r){
    h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
    h._hjSettings={hjid:191585,hjsv:6};
    a=o.getElementsByTagName('head')[0];
    r=o.createElement('script');r.async=1;
    r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
    a.appendChild(r);
})(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');

document.addEventListener("page:change", function(event) {
  hj('stateChange', location.pathname);
});</script><meta name="csrf-param" content="authenticity_token" />
<meta name="csrf-token" content="FunI7pUeKM81McPio9876yRY3bPCSJMfoRt2NRSiaY7YDoZZf6gZqaSyxGOFEJ+fHf0tBsrCx6wVhL/Nv5qmbQ==" /></head><body class="drugs-c show-a"><header><nav class="navbar fixed-top navbar-expand-custom navbar-light" id="main-nav" style="background-color: #ff00b8;"><a class="navbar-brand" href="/"><img height="20" src="/assets/logo-white-dd185d748ee0164b8ee8f88df29235cd8cfc7936a3c974589262c667e9294219.svg" alt="Logo white" /></a><button aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation" class="navbar-toggler navbar-toggler-right" data-target="#navbar" data-toggle="collapse" type="button"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbar"><ul class="navbar-nav ml-auto"><li class="nav-item dropdown"><a class="nav-link dropdown-toggle" data-toggle="dropdown" href="#">Browse</a><div class="dropdown-menu"><a class="dropdown-item" href="/drugs"><div class="icon-circle drugbank-icon icon-drugs"><svg class="icon" role="img" title="drugs"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#drugs"> </use></svg></div> Drugs</a><a class="dropdown-item" href="/categories"><div class="icon-circle drugbank-icon icon-categories"><svg class="icon" role="img" title="categories"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#categories"> </use></svg></div> Categories</a><a class="dropdown-item" href="/pathways"><div class="icon-circle drugbank-icon icon-pathways"><svg class="icon" role="img" title="pathways"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#pathways"> </use></svg></div> Pathways</a><a class="dropdown-item" href="/reactions"><div class="icon-circle drugbank-icon icon-reactions"><svg class="icon" role="img" title="reactions"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#reactions"> </use></svg></div> Drug Reactions</a><a class="dropdown-item" href="/classyfication"><div class="icon-circle drugbank-icon icon-classifications"><svg class="icon" role="img" title="classifications"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#classifications"> </use></svg></div> Drug Classification</a><a class="dropdown-item" href="/targets"><div class="icon-circle drugbank-icon icon-targets"><svg class="icon" role="img" title="targets"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#targets"> </use></svg></div> Drug Targets</a><div class="dropdown-divider"></div><a class="dropdown-item" href="/pharmaco/genomics"><div class="icon-circle drugbank-icon icon-geno-browse"><svg class="icon" role="img" title="geno-browse"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#geno-browse"> </use></svg></div> Pharmaco-genomics</a><a class="dropdown-item" href="/pharmaco/metabolomics"><div class="icon-circle drugbank-icon icon-chemquery"><svg class="icon" role="img" title="chemquery"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#chemquery"> </use></svg></div> Pharmaco-metabolomics</a><a class="dropdown-item" href="/pharmaco/transcriptomics"><div class="icon-circle drugbank-icon icon-interax"><svg class="icon" role="img" title="interax"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#interax"> </use></svg></div> Pharmaco-transcriptomics</a><a class="dropdown-item" href="/pharmaco/proteomics"><div class="icon-circle drugbank-icon icon-interax"><svg class="icon" role="img" title="interax"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#interax"> </use></svg></div> Pharmaco-proteomics</a></div></li><li class="nav-item"><a class="nav-link" href="/covid-19">COVID-19</a></li><li class="nav-item dropdown"><a class="nav-link dropdown-toggle" data-toggle="dropdown" href="#">Search</a><div class="dropdown-menu"><a data-no-turbolink="true" class="dropdown-item" href="/structures/search/small_molecule_drugs/structure"><div class="icon-circle drugbank-icon icon-chemquery"><svg class="icon" role="img" title="chemquery"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#chemquery"> </use></svg></div> Chemical Structure</a><a data-no-turbolink="true" class="dropdown-item" href="/structures/search/small_molecule_drugs/mass"><div class="icon-circle drugbank-icon icon-molecular-weight"><svg class="icon" role="img" title="molecular-weight"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#molecular-weight"> </use></svg></div> Molecular Weight</a><a class="dropdown-item" href="/interax/multi_search"><div class="icon-circle drugbank-icon icon-interax"><svg class="icon" role="img" title="interax"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#interax"> </use></svg></div> Drug & Food Interactions</a><a class="dropdown-item" href="/structures/search/bonds/sequence"><div class="icon-circle drugbank-icon icon-sequence"><svg class="icon" role="img" title="sequence"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#sequence"> </use></svg></div> Target Sequences</a><a class="dropdown-item" data-no-turbolink="true" href="/pharmaco/search"><div class="icon-circle drugbank-icon icon-pathways"><svg class="icon" role="img" title="pathways"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#pathways"> </use></svg></div> Pharmaco-omics</a><a class="dropdown-item" href="/unearth/advanced/drugs"><div class="icon-circle drugbank-icon icon-advanced"><svg class="icon" role="img" title="advanced"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#advanced"> </use></svg></div> Advanced Search</a><div class="dropdown-divider"></div><a class="dropdown-item" href="/spectra/ms/search"><div class="icon-circle drugbank-icon icon-ms"><svg class="icon" role="img" title="ms"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#ms"> </use></svg></div> MS Search</a><a class="dropdown-item" href="/spectra/ms_ms/search"><div class="icon-circle drugbank-icon icon-msms"><svg class="icon" role="img" title="msms"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#msms"> </use></svg></div> MS/MS Search</a><a class="dropdown-item" href="/spectra/c_ms/search"><div class="icon-circle drugbank-icon icon-gcms"><svg class="icon" role="img" title="gcms"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#gcms"> </use></svg></div> GC/MS Search</a><a class="dropdown-item" href="/spectra/nmr/one_d/search/new"><div class="icon-circle drugbank-icon icon-nmr-1d"><svg class="icon" role="img" title="nmr-1d"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#nmr-1d"> </use></svg></div> 1D NMR Search</a><a class="dropdown-item" href="/spectra/nmr_two_d/search"><div class="icon-circle drugbank-icon icon-nmr-2d"><svg class="icon" role="img" title="nmr-2d"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#nmr-2d"> </use></svg></div> 2D NMR Search</a></div></li><li class="nav-item"><a class="nav-link" href="/releases/latest">Downloads</a></li><li class="nav-item dropdown" role="presentation"><a class="nav-link dropdown-toggle" data-toggle="dropdown" href="#">Commercial Data</a><div class="dropdown-menu"><div class="link-header dropdown-item">Products</div><a class="dropdown-item" target="_blank" href="https://drugbankplus.com/clinical"><div class="icon-pink product-icon drugbank-icon icon-clinical"><svg class="icon" role="img" title="clinical">  <use xlink:href="/assets/plus/icons-e72094aba38f3198473ad5627a27324d7949d4faa8c18f87c3a4dfce7466f68e.svg#clinical"> </use></svg></div> Clinical Drug Data</a><a class="dropdown-item" target="_blank" href="https://drugbankplus.com/scientific"><div class="icon-pink product-icon drugbank-icon icon-scientific"><svg class="icon" role="img" title="scientific"> <use xlink:href="/assets/plus/icons-e72094aba38f3198473ad5627a27324d7949d4faa8c18f87c3a4dfce7466f68e.svg#scientific"> </use></svg></div> Scientific Drug Data</a><div class="link-header dropdown-item">Industries</div><a class="dropdown-item" target="_blank" href="https://drugbankplus.com/discover">Drug Discovery</a><a class="dropdown-item" target="_blank" href="https://drugbankplus.com/repurpose">Drug Repurposing</a><a class="dropdown-item" target="_blank" href="https://drugbankplus.com/precision">Precision Medicine</a><a class="dropdown-item" target="_blank" href="https://drugbankplus.com/ai">Machine Learning</a><div class="link-header dropdown-item">Resources</div><a class="dropdown-item" target="_blank" href="https://drugbankplus.com/downloads">White Papers</a></div></li><li class="nav-item dropdown"><a class="nav-link dropdown-toggle" data-toggle="dropdown" href="#">Help</a><div class="dropdown-menu right-menu"><div class="link-header dropdown-item"><a target="_blank" href="https://dev.drugbankplus.com/guides/index"><div class=" drugbank-icon icon-help_center"><svg class="icon" role="img" title="help_center"> <use xlink:href="/assets/plus/icons-e72094aba38f3198473ad5627a27324d7949d4faa8c18f87c3a4dfce7466f68e.svg#help_center"> </use></svg></div> Help Center</a></div><div class="link-subheader"> Quick Links</div><a class="dropdown-item" target="_blank" href="https://dev.drugbankplus.com/guides/drugbank/citing"><div class="icon-circle drugbank-icon icon-citing"><svg class="icon" role="img" title="citing"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#citing"> </use></svg></div> Citing DrugBank</a><a class="dropdown-item" target="_blank" href="https://dev.drugbankplus.com/guides/faqs"><div class="icon-circle drugbank-icon icon-faq"><svg class="icon" role="img" title="faq"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#faq"> </use></svg></div> DrugBank.ca FAQs</a><a class="dropdown-item" target="_blank" href="https://dev.drugbankplus.com/guides/drugbank/searching"><div class="icon-circle drugbank-icon icon-search"><svg class="icon" role="img" title="search"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#search"> </use></svg></div> Searching DrugBank</a><a class="dropdown-item" target="_blank" href="https://dev.drugbankplus.com/guides/drugbank/other_databases"><div class="icon-circle drugbank-icon icon-database"><svg class="icon" role="img" title="database"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#database"> </use></svg></div> Other Databases</a><a class="dropdown-item" target="_blank" href="https://dev.drugbankplus.com/guides/fields/drugs"><div class="icon-circle drugbank-icon icon-data-sources"><svg class="icon" role="img" title="data-sources"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#data-sources"> </use></svg></div> Data Sources</a></div></li><li class="nav-item dropdown"><a class="nav-link dropdown-toggle" data-toggle="dropdown" href="#">About</a><div class="dropdown-menu right-menu"><a class="dropdown-item" href="/about"><div class="icon-circle drugbank-icon icon-drugbank"><svg class="icon" role="img" title="drugbank"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#drugbank"> </use></svg></div> About DrugBank.ca</a><a class="dropdown-item" href="/stats"><div class="icon-circle drugbank-icon icon-statistics"><svg class="icon" role="img" title="statistics"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#statistics"> </use></svg></div> Statistics</a><a class="dropdown-item" target="_blank" rel="noopener" href="https://blog.drugbankplus.com/"><div class="icon-circle drugbank-icon icon-news"><svg class="icon" role="img" title="news"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#news"> </use></svg></div> Blog</a><a target="_blank" rel="noopener" class="dropdown-item" href="http://www.wishartlab.com"><div class="icon-circle drugbank-icon icon-wishart"><svg class="icon" role="img" title="wishart"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#wishart"> </use></svg></div> Wishart Research Group</a><a class="dropdown-item" href="/contact"><div class="small-icon icon-circle drugbank-icon icon-paper-plane"><svg class="icon" role="img" title="paper-plane"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#paper-plane"> </use></svg></div> Contact Us</a></div></li></ul></div></nav><nav class="navbar fixed-top navbar-expand search-bar justify-content-center justify-content-sm-end d-flex has-banner"><div class="mini-banner ad-banner"><div class="close-ad"><div class="drugbank-icon icon-cross"><svg class="icon" role="img" title="cross"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#cross"> </use></svg></div></div><div class="banner-text"><span></span><a class="banner-link track-link" target="_blank" href="">Read More</a></div></div><form class="form-inline" action="/unearth/q" accept-charset="UTF-8" method="get"><input name="utf8" type="hidden" value="&#x2713;" /><div class="search-group d-none d-sm-block" style="margin-right: 0.5rem;"><select name="searcher" id="searcher" class="form-control input-md"><option value="drugs">Drugs</option>
<option value="bio_entities">Targets</option>
<option value="pathways">Pathways</option>
<option value="indications">Indications</option></select> <div class="drugbank-icon icon-arrow-down"><svg class="icon" role="img" title="arrow-down"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#arrow-down"> </use></svg></div> </div><div class="search-group"><input type="text" name="query" id="query" class="search-query" /> <div class="drugbank-icon icon-search"><svg class="icon" role="img" title="search"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#search"> </use></svg></div> </div></form></nav></header><main role="main"><div class="content-container"><div id="jumper-tab"><div class="jumper-toggle drugbank-icon icon-double-arrow-left"><svg class="icon" role="img" title="double-arrow-left"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#double-arrow-left"> </use></svg></div></div><div class="list-group closed" id="jumper"><div class="list-group-item jumper-header d-flex justify-content-between align-items-center">Jump to section<div class="jumper-toggle drugbank-icon icon-double-arrow-right"><svg class="icon" role="img" title="double-arrow-right"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#double-arrow-right"> </use></svg></div></div><a class="list-group-item jumper-link" href="#identification"><div class="circle"></div>Identification</a><a class="list-group-item jumper-link" href="#pharmacology"><div class="circle"></div>Pharmacology</a><a class="list-group-item jumper-link" href="#interactions"><div class="circle"></div>Interactions</a><a class="list-group-item jumper-link" href="#references"><div class="circle"></div>References</a><a class="list-group-item jumper-link" href="#clinical-trials"><div class="circle"></div>Trials</a><a class="list-group-item jumper-link" href="#pharmacoeconomics"><div class="circle"></div>Economics</a><a class="list-group-item jumper-link" href="#properties"><div class="circle"></div>Properties</a><a class="list-group-item jumper-link" href="#spectra"><div class="circle"></div>Spectra</a><a class="list-group-item jumper-link" href="#taxonomy"><div class="circle"></div>Taxonomy</a></div><div class="content-header d-sm-flex align-items-center"><h1 class="align-self-center mr-4">Lapatinib</h1><div class="page-actions justify-content-sm-end mt-2 mt-sm-0"><div class="bond-links"><a class="btn bond-link targets" href="#targets">Targets (2)</a><a class="btn bond-link enzymes" href="#enzymes">Enzymes (4)</a><a class="btn bond-link transporters" href="#transporters">Transporters (2)</a><a class="btn biointeractions-link btn-pink" href="/drugs/DB01259/biointeractions">Biointeractions (10)</a></div></div></div><div class="card-content px-md-4 px-sm-2 pb-md-4 pb-sm-2"><h2 id="identification" class="section-header">Identification</h2><dl><dt class="col-md-2 col-sm-4">Name</dt><dd class="col-md-10 col-sm-8">Lapatinib</dd><dt class="col-md-2 col-sm-4">Accession Number</dt><dd class="col-md-10 col-sm-8">DB01259&nbsp; (DB02584) </dd><dt class="col-md-2 col-sm-4">Type</dt><dd class="col-md-10 col-sm-8">Small Molecule</dd><dt class="col-md-2 col-sm-4">Groups</dt><dd class="col-md-10 col-sm-8">Approved, Investigational</dd><dt class="col-md-2 col-sm-4">Description</dt><dd class="col-md-10 col-sm-8"><p>Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.</p>
</dd><dt class="col-md-2 col-sm-4">Structure</dt><dd class="col-md-10 col-sm-8"><div class="structure"><a class="moldbi-vector-thumbnail" href="/structures/DB01259/image.svg"><img src="/structures/DB01259/thumb.svg" alt="Thumb" /></a></div><div class="structure-links"><div class="btn-group btn-group-sm" data-no-turbolink=""><a data-toggle="modal" class="btn btn-outline-secondary" rel="nofollow" href="#structure-zoom"><div class="drugbank-icon icon-zoom-in"><svg class="icon" role="img" title="zoom-in"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#zoom-in"> </use></svg></div></a><a class="btn btn-outline-secondary" rel="nofollow" href="/structures/small_molecule_drugs/DB01259">3D</a><div class="btn-group btn-group-sm" id="structure-download"><button aria-expanded="false" aria-haspopup="true" class="btn btn-outline-secondary dropdown-toggle" data-toggle="dropdown" id="structure-download" type="button">Download </button><div aria-labelledby="structure-download" class="dropdown-menu"><a class="dropdown-item" rel="nofollow" href="/structures/small_molecule_drugs/DB01259.mol">MOL</a><a class="dropdown-item" rel="nofollow" href="/structures/small_molecule_drugs/DB01259.sdf">SDF</a><a class="dropdown-item" rel="nofollow" href="/structures/small_molecule_drugs/DB01259.sdf?type=3d">3D-SDF</a><a class="dropdown-item" rel="nofollow" href="/structures/small_molecule_drugs/DB01259.pdb">PDB</a><a class="dropdown-item" rel="nofollow" href="/structures/small_molecule_drugs/DB01259.smiles">SMILES</a><a class="dropdown-item" rel="nofollow" href="/structures/small_molecule_drugs/DB01259.inchi">InChI</a></div></div><a class="btn btn-outline-secondary" rel="nofollow" href="/structures/search/small_molecule_drugs/structure?database_id=DB01259&amp;search_type=similarity#results"><div class="drugbank-icon icon-chemquery"><svg class="icon" role="img" title="chemquery"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#chemquery"> </use></svg></div> Similar Structures</a></div><div class="modal fade" id="structure-zoom"><div class="modal-dialog modal-lg" role="document"><div class="modal-content"><div class="modal-header"><h4 class="modal-title">Structure for Lapatinib (DB01259)</h4><button aria-hidden="true" class="close" data-dismiss="modal" type="button"><span aria-hidden="true">&times;</span></button></div><div class="modal-body"><div class="d-flex justify-content-center"><img src="/structures/DB01259/image.svg" alt="Image" /></div></div><div class="modal-footer"><button class="btn btn-default" data-dismiss="modal" type="button"> Close</button></div></div></div></div></div></dd><dt class="col-md-2 col-sm-4">Synonyms</dt><dd class="col-md-10 col-sm-8"><ul class="list-unstyled table-list-break"><li>Lapatinib</li>
<li>N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine</li></ul></dd><dt class="col-md-2 col-sm-4">External IDs <a tabindex="0" role="button" data-toggle="popover" data-content="Codes and identifiers used by other resources and companies, often used before choosing a marketing name." title="About External Identifiers" id="external-identifiers-info" class="drug-info-popup" href="javascript:void(0);"><div class="drugbank-icon icon-information"><svg class="icon" role="img" title="information"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#information"> </use></svg></div></a></dt><dd class="col-md-10 col-sm-8"><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item">GSK-572016</span><span class='list-separator'> / </span><span class="separated-list-item">GW 572016</span><span class='list-separator'> / </span><span class="separated-list-item">GW-572016X</span><span class='list-separator'> / </span><span class="separated-list-item">GW572016</span></span></span></dd><dt class="col-md-2 col-sm-4">Product Ingredients <a tabindex="0" role="button" data-toggle="popover" data-content="Active ingredients including salts and other forms of exact ingredients used in drug products." title="About Product Ingredients" id="product-ingredients-info" class="drug-info-popup" href="javascript:void(0);"><div class="drugbank-icon icon-information"><svg class="icon" role="img" title="information"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#information"> </use></svg></div></a></dt><dd class="col-md-10 col-sm-8"><table class="table table-sm responsive-table" id="drug-salts-table"><thead><tr><th>Ingredient</th><th>UNII</th><th>CAS</th><th>InChI Key</th></tr></thead><tbody><tr><td><strong><a href="/salts/DBSALT001785">Lapatinib ditosylate</a></strong></td><td><a target="_blank" rel="noopener" href="http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=G873GX646R">G873GX646R</a></td><td>388082-78-8</td><td>XNRVGTHNYCNCFF-UHFFFAOYSA-N</td></tr></tbody></table></dd><dt class="col-md-2 col-sm-4">Product Images</dt><dd class="col-md-10 col-sm-8"><div id="product-carousel-row" style="max-width: 592px"><div class="carousel slide" data-active="false" id="product-carousel"><ol class="carousel-indicators"><li class="active" data-slide-to="0" data-target="#product-carousel"></li></ol><div class="carousel-inner"><div class="carousel-item w-100 active"><a class="package-picture" data-toggle="modal" data-url="//s3-us-west-2.amazonaws.com/drugbank/product_images/images/medium/00173-0752-00_NLMIMAGE10_8318C1B6.jpg?1498433299" data-fullurl="//s3-us-west-2.amazonaws.com/drugbank/product_images/images/original/00173-0752-00_NLMIMAGE10_8318C1B6.jpg?1498433299" data-description="lapatinib 250 MG Oral Tablet [Tykerb]" href="#modal-package"><img class="img-fluid" src="//s3-us-west-2.amazonaws.com/drugbank/product_images/images/thumb/00173-0752-00_NLMIMAGE10_8318C1B6.jpg?1498433299" /></a></div></div></div></div></dd><dt class="col-md-2 col-sm-4">Prescription Products</dt><dd class="col-md-10 col-sm-8 has-locked-content"><table class="products table table-sm dt-responsive datatable-remote" data-source="/drugs/DB01259/products.json?group=approved" data-total="10" id="approved-products" style="width: 100%"><thead><tr><th>Name</th><th>Dosage</th><th>Strength</th><th>Route</th><th>Labeller</th><th>Marketing Start</th><th>Marketing End</th><th></th><th class="drug-image"></th></tr><tr class="unlock-row"><th class="no-sort" colspan="9"><div class="locked-link" data-field="approved-products" data-target="#locked-modal" data-toggle="modal"><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div> Unlock Additional Data</div></th></tr></thead><tbody><tr><td>Tykerb</td><td>Tablet</td><td>250 mg/1</td><td>Oral</td><td>Glaxosmithkline Inc</td><td>2007-03-16</td><td>2017-11-30</td><td><span class="country"><span hidden="hidden">US</span><img src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg" alt="Us" /></span></td><td><a class="package-picture" data-toggle="modal" data-url="//s3-us-west-2.amazonaws.com/drugbank/product_images/images/medium/00173-0752-00_NLMIMAGE10_8318C1B6.jpg?1498433299" data-fullurl="//s3-us-west-2.amazonaws.com/drugbank/product_images/images/original/00173-0752-00_NLMIMAGE10_8318C1B6.jpg?1498433299" data-description="lapatinib 250 MG Oral Tablet [Tykerb]" href="#modal-package"><img class="package-thumb" src="//s3-us-west-2.amazonaws.com/drugbank/product_images/images/tiny/00173-0752-00_NLMIMAGE10_8318C1B6.jpg?1498433299" alt="00173 0752 00 nlmimage10 8318c1b6" /></a></td></tr><tr><td>Tykerb</td><td>Tablet</td><td>250 mg</td><td>Oral</td><td>Novartis</td><td>2009-06-05</td><td><span class='not-available'>Not applicable</span></td><td><span class="country"><span hidden="hidden">Canada</span><img src="/assets/countries/canada-64ffe8c476c257597eca3ded684da90a2b1a500bd6389ebd2ca5e213b1cc7574.svg" alt="Canada" /></span></td><td></td></tr><tr><td>Tykerb</td><td>Tablet</td><td>250 mg/1</td><td>Oral</td><td>Novartis Pharmaceuticals Corporation</td><td>2016-08-03</td><td><span class='not-available'>Not applicable</span></td><td><span class="country"><span hidden="hidden">US</span><img src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg" alt="Us" /></span></td><td></td></tr><tr><td>Tyverb</td><td>Tablet, film coated</td><td>250 mg</td><td>Oral</td><td>Novartis Europharm Limited</td><td>2008-06-10</td><td><span class='not-available'>Not applicable</span></td><td><span class="country"><span hidden="hidden">EU</span><img src="/assets/countries/eu-dda0a77d72bbe9085912a87221977afb68d43d8dbf280688345b7a73f2498514.svg" alt="Eu" /></span></td><td></td></tr><tr><td>Tyverb</td><td>Tablet, film coated</td><td>250 mg</td><td>Oral</td><td>Novartis Europharm Limited</td><td>2008-06-10</td><td><span class='not-available'>Not applicable</span></td><td><span class="country"><span hidden="hidden">EU</span><img src="/assets/countries/eu-dda0a77d72bbe9085912a87221977afb68d43d8dbf280688345b7a73f2498514.svg" alt="Eu" /></span></td><td></td></tr><tr><td>Tyverb</td><td>Tablet, film coated</td><td>250 mg</td><td>Oral</td><td>Novartis Europharm Limited</td><td>2008-06-10</td><td><span class='not-available'>Not applicable</span></td><td><span class="country"><span hidden="hidden">EU</span><img src="/assets/countries/eu-dda0a77d72bbe9085912a87221977afb68d43d8dbf280688345b7a73f2498514.svg" alt="Eu" /></span></td><td></td></tr><tr><td>Tyverb</td><td>Tablet, film coated</td><td>250 mg</td><td>Oral</td><td>Novartis Europharm Limited</td><td>2008-06-10</td><td><span class='not-available'>Not applicable</span></td><td><span class="country"><span hidden="hidden">EU</span><img src="/assets/countries/eu-dda0a77d72bbe9085912a87221977afb68d43d8dbf280688345b7a73f2498514.svg" alt="Eu" /></span></td><td></td></tr><tr><td>Tyverb</td><td>Tablet, film coated</td><td>250 mg</td><td>Oral</td><td>Novartis Europharm Limited</td><td>2008-06-10</td><td><span class='not-available'>Not applicable</span></td><td><span class="country"><span hidden="hidden">EU</span><img src="/assets/countries/eu-dda0a77d72bbe9085912a87221977afb68d43d8dbf280688345b7a73f2498514.svg" alt="Eu" /></span></td><td></td></tr><tr><td>Tyverb</td><td>Tablet, film coated</td><td>250 mg</td><td>Oral</td><td>Novartis Europharm Limited</td><td>2008-06-10</td><td><span class='not-available'>Not applicable</span></td><td><span class="country"><span hidden="hidden">EU</span><img src="/assets/countries/eu-dda0a77d72bbe9085912a87221977afb68d43d8dbf280688345b7a73f2498514.svg" alt="Eu" /></span></td><td></td></tr><tr><td>Tyverb</td><td>Tablet, film coated</td><td>250 mg</td><td>Oral</td><td>Novartis Europharm Limited</td><td>2008-06-10</td><td><span class='not-available'>Not applicable</span></td><td><span class="country"><span hidden="hidden">EU</span><img src="/assets/countries/eu-dda0a77d72bbe9085912a87221977afb68d43d8dbf280688345b7a73f2498514.svg" alt="Eu" /></span></td><td></td></tr></tbody></table><div class="locked-fields-holder" data-for="#approved-products"><div class="locked-fields closed" data-collapsed="collapsed"><div class="locked-tab"><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div><span class="tab-label">Additional Data Available</span><div class="drugbank-icon icon-arrow-left"><svg class="icon" role="img" title="arrow-left"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#arrow-left"> </use></svg></div><div class="drugbank-icon icon-arrow-right"><svg class="icon" role="img" title="arrow-right"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#arrow-right"> </use></svg></div></div><ul class="locked-accordion"><div class="flex-content"><li class="closed"><div class="flex-content"><div class="locked-header">Application Number <div class="drugbank-icon icon-plus"><svg class="icon" role="img" title="plus"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#plus"> </use></svg></div></div><div class="locked-content"><div class="locked-info"><div class="close-tab drugbank-icon icon-exit"><svg class="icon" role="img" title="exit"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#exit"> </use></svg></div><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div><div class="locked-panel-header">Application Number</div><p>A unique ID assigned by the FDA when a product is submitted for approval by the labeller.</p><a class="btn btn-sm btn-pink track-link" target="_blank" data-link-id="locked/approved-products-application-number" href="https://drugbankplus.com/scientific">Learn more</a></div></div></div></li><li class="closed"><div class="flex-content"><div class="locked-header">Product Code <div class="drugbank-icon icon-plus"><svg class="icon" role="img" title="plus"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#plus"> </use></svg></div></div><div class="locked-content"><div class="locked-info"><div class="close-tab drugbank-icon icon-exit"><svg class="icon" role="img" title="exit"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#exit"> </use></svg></div><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div><div class="locked-panel-header">Product Code</div><p>A governmentally-recognized ID which uniquely identifies the product within its regulatory market.</p><a class="btn btn-sm btn-pink track-link" target="_blank" data-link-id="locked/approved-products-product-code" href="https://drugbankplus.com/scientific">Learn more</a></div></div></div></li></div></ul></div></div></dd><dt class="col-md-2 col-sm-4">International/Other Brands</dt><dd class="col-md-10 col-sm-8"><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item">Tycerb</span></span></span></dd><dt class="col-md-2 col-sm-4">Categories</dt><dd class="col-md-10 col-sm-8"><div class="category-columns"><ul class="list-unstyled table-list"><li><a href="/categories/DBCAT000024">Antineoplastic Agents</a></li>
<li><a href="/categories/DBCAT002086">Antineoplastic and Immunomodulating Agents</a></li>
<li><a href="/categories/DBCAT002638">Cytochrome P-450 CYP2C19 Substrates</a></li>
<li><a href="/categories/DBCAT000868">Cytochrome P-450 CYP2C8 Inhibitors</a></li>
<li><a href="/categories/DBCAT004479">Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)</a></li>
<li><a href="/categories/DBCAT002642">Cytochrome P-450 CYP2C8 Substrates</a></li>
<li><a href="/categories/DBCAT000934">Cytochrome P-450 CYP3A Inhibitors</a></li>
<li><a href="/categories/DBCAT003919">Cytochrome P-450 CYP3A Substrates</a></li>
<li><a href="/categories/DBCAT003232">Cytochrome P-450 CYP3A4 Inhibitors</a></li>
<li><a href="/categories/DBCAT002713">Cytochrome P-450 CYP3A4 Inhibitors (weak)</a></li>
<li><a href="/categories/DBCAT002646">Cytochrome P-450 CYP3A4 Substrates</a></li>
<li><a href="/categories/DBCAT003807">Cytochrome P-450 CYP3A5 Substrates</a></li>
<li><a href="/categories/DBCAT000394">Cytochrome P-450 Enzyme Inhibitors</a></li>
<li><a href="/categories/DBCAT005101">Cytochrome P-450 Substrates</a></li>
<li><a href="/categories/DBCAT000003">Enzyme Inhibitors</a></li>
<li><a href="/categories/DBCAT005097">Hepatotoxic Agents</a></li>
<li><a href="/categories/DBCAT004973">Heterocyclic Compounds, Fused-Ring</a></li>
<li><a href="/categories/DBCAT003325">Kinase Inhibitor</a></li>
<li><a href="/categories/DBCAT002667">P-glycoprotein inhibitors</a></li>
<li><a href="/categories/DBCAT002691">Potential QTc-Prolonging Agents</a></li>
<li><a href="/categories/DBCAT000737">Protein Kinase Inhibitors</a></li>
<li><a href="/categories/DBCAT003823">QTc Prolonging Agents</a></li>
<li><a href="/categories/DBCAT000883">Quinazolines</a></li>
<li><a href="/categories/DBCAT001447">Tyrosine Kinase Inhibitors</a></li></ul></div></dd><dt class="col-md-2 col-sm-4">UNII</dt><dd class="col-md-10 col-sm-8"><a target="_blank" rel="noopener" href="http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=0VUA21238F">0VUA21238F</a></dd><dt class="col-md-2 col-sm-4">CAS number</dt><dd class="col-md-10 col-sm-8">231277-92-2</dd><dt class="col-md-2 col-sm-4">Weight</dt><dd class="col-md-10 col-sm-8">Average: 581.058 <br />Monoisotopic: 580.134731942 </dd><dt class="col-md-2 col-sm-4">Chemical Formula</dt><dd class="col-md-10 col-sm-8">C<sub>29</sub>H<sub>26</sub>ClFN<sub>4</sub>O<sub>4</sub>S</dd><dt class="col-md-2 col-sm-4">InChI Key</dt><dd class="col-md-10 col-sm-8">BCFGMOOMADDAQU-UHFFFAOYSA-N</dd><dt class="col-md-2 col-sm-4">InChI</dt><dd class="col-md-10 col-sm-8"><div class="wrap">InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)</div></dd><dt class="col-md-2 col-sm-4">IUPAC Name</dt><dd class="col-md-10 col-sm-8"><div class="wrap">N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine</div></dd><dt class="col-md-2 col-sm-4">SMILES</dt><dd class="col-md-10 col-sm-8"><div class="wrap">CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1</div></dd></dl><h2 id="pharmacology" class="section-header">Pharmacology</h2><dl><dt class="col-md-2 col-sm-4">Indication</dt><dd class="col-md-10 col-sm-8"><p>Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.</p>
</dd><dt class="col-md-2 col-sm-4">Associated Conditions</dt><dd class="col-md-10 col-sm-8"><ul class="list-unstyled table-list"><li><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></li>
<li><a href="/indications/DBCOND0023190">Refractory, advanced Breast cancer</a></li>
<li><a href="/indications/DBCOND0023213">Refractory, metastatic Breast cancer</a></li></ul></dd><dt class="col-md-2 col-sm-4">Pharmacodynamics</dt><dd class="col-md-10 col-sm-8"><p>Lapatinib is a small molecule and a member of the 4-anilinoquinazoline class of kinase inhibitors. An anti-cancer drug, lapatinib was developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. </p>
</dd><dt class="col-md-2 col-sm-4">Mechanism of action</dt><dd class="col-md-10 col-sm-8"><p>Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both epidermal growth factor receptor (HER1/EGFR/ERBB1) and human epidermal growth factor receptor type 2 (HER2/ERBB2)with a dissociation half-life of &ge;300 minutes. Lapatinib inhibits ERBB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-florouracil (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.</p>
<table class="table table-sm responsive-table" id="drug-moa-target-table"><thead><tr><th>Target</th><th>Actions</th><th>Organism</th></tr></thead><tbody><tr><td><span class="badge badge-pill badge-yes mr-2 tips" title="Pharmacologically Active">A</span><a href="#BE0000767">Epidermal growth factor receptor</a></td><td><div class="label label-default">antagonist</div></td><td>Humans</td></tr><tr><td><span class="badge badge-pill badge-yes mr-2 tips" title="Pharmacologically Active">A</span><a href="#BE0000511">Receptor tyrosine-protein kinase erbB-2</a></td><td><div class="label label-default">antagonist</div></td><td>Humans</td></tr></tbody></table></dd><div class="col-sm-12 locked-section-container"><div class="locked-section-flex"><div class="locked-section-row locked-link" data-field="adv-cont-bb" data-target="#locked-modal" data-toggle="modal"><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div> Unlock Additional Data</div><div class="locked-section-box"><div class="locked-header"><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div> Additional Data Available</div><div class="locked-content"><div class="locked-info"><div class="locked-panel-header">Adverse Effects</div><p>Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.</p><a class="btn btn-sm btn-pink track-link" target="_blank" data-link-id="locked/adverse-effects" href="https://drugbankplus.com/scientific">Learn more</a></div></div></div><div class="locked-section-box"><div class="locked-header"><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div> Additional Data Available</div><div class="locked-content"><div class="locked-info"><div class="locked-panel-header">Contraindications</div><p>Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.</p><a class="btn btn-sm btn-pink track-link" target="_blank" data-link-id="locked/contraindications" href="https://drugbankplus.com/scientific">Learn more</a></div></div></div><div class="locked-section-box"><div class="locked-header"><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div> Additional Data Available</div><div class="locked-content"><div class="locked-info"><div class="locked-panel-header">Blackbox Warnings</div><p>Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.</p><a class="btn btn-sm btn-pink track-link" target="_blank" data-link-id="locked/blackbox-warnings" href="https://drugbankplus.com/scientific">Learn more</a></div></div></div></div></div><dt class="col-md-2 col-sm-4">Absorption</dt><dd class="col-md-10 col-sm-8"><p>Absorption following oral administration of lapatinib is incomplete and variable.</p>
</dd><dt class="col-md-2 col-sm-4">Volume of distribution</dt><dd class="col-md-10 col-sm-8"><span class='not-available'>Not Available</span></dd><dt class="col-md-2 col-sm-4">Protein binding</dt><dd class="col-md-10 col-sm-8"><p>Highly bound (&gt;99%) to albumin and alpha-1 acid glycoprotein</p>
</dd><dt class="col-md-2 col-sm-4">Metabolism</dt><dd class="col-md-10 col-sm-8"><p><p>Lapatinib undergoes extensive metabolism, primarily by CYP3A4 and CYP3A5, with minor contributions from CYP2C19 and CYP2C8 to a variety of oxidated metabolites, none of which accounts for more than 14% of the dose recovered in the feces or 10% of lapatinib concentration in plasma.</p>
</p></dd><dt class="col-md-2 col-sm-4">Route of elimination</dt><dd class="col-md-10 col-sm-8"><p>Lapatinib undergoes extensive metabolism, primarily by CYP3A4 and CYP3A5, with minor contributions from CYP2C19 and CYP2C8 to a variety of oxidated metabolites, none of which accounts for more than 14% of the dose recovered in the feces or 10% of lapatinib concentration in plasma.</p>
</dd><dt class="col-md-2 col-sm-4">Half life</dt><dd class="col-md-10 col-sm-8"><p>Single-dose terminal half life: 14.2 hours
Effective multiple-dose half life: 24 hours</p>
</dd><dt class="col-md-2 col-sm-4">Clearance</dt><dd class="col-md-10 col-sm-8"><span class='not-available'>Not Available</span></dd><dt class="col-md-2 col-sm-4">Toxicity</dt><dd class="col-md-10 col-sm-8"><p>There has been a report of one patient who took 3,000 mg of lapatinib for 10 days. This patient had grade 3 diarrhea and vomiting on day 10.</p>
</dd><dt class="col-md-2 col-sm-4">Affected organisms</dt><dd class="col-md-10 col-sm-8"><ul class="list-unstyled table-list"><li>Humans and other mammals</li></ul></dd><dt class="col-md-2 col-sm-4">Pathways</dt><dd class="col-md-10 col-sm-8"><span class='not-available'>Not Available</span></dd><dt class="col-md-2 col-sm-4">Pharmacogenomic Effects/ADRs <a tabindex="0" role="button" data-toggle="popover" data-content="SNP Mediated Pharmacological Effects and Adverse Drug Reactions (ADRs) is a compilation of drug-specific pharmacogenomic information from various sources and primary literature. &mdash; <a target=&quot;_blank&quot; href=&quot;/snp_actions&quot;>Browse all</a>" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);"><div class="drugbank-icon icon-information"><svg class="icon" role="img" title="information"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#information"> </use></svg></div></a></dt><dd class="col-md-10 col-sm-8"><table class="table table-sm table-bordered datatable dt-responsive" style="width: 100%"><thead><tr><th>Interacting Gene/Enzyme</th><th>Allele name</th><th>Genotype(s)</th><th>Defining Change(s)</th><th class="no-sort">Type(s)</th><th>Description</th><th class="no-sort">Details</th></tr></thead><tbody><tr><td><strong>HLA class II histocompatibility antigen, DQ alpha 1 chain</strong></td><td>HLA-DQA1*02:01</td><td><span class='not-available'>Not Available</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item">HLA-DQA1*02</span></span></span></td><td><span class="label label-danger basic-tip" title="SNP-Mediated Adverse Drug Reaction">ADR</span> <span class="label label-success basic-tip" title="Directly studied, with clinical relevance">Directly Studied</span></td><td>The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.</td><td class="text-sm-center"><a class="btn btn-sm btn-outline-secondary" href="/pharmaco/genomics/DBSNPE000262">Details</a></td></tr><tr><td><strong>HLA class II histocompatibility antigen, DRB1-11 beta chain</strong></td><td>HLA-DRB1*07:01</td><td><span class='not-available'>Not Available</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item">HLA-DRB1*07</span></span></span></td><td><span class="label label-danger basic-tip" title="SNP-Mediated Adverse Drug Reaction">ADR</span> <span class="label label-success basic-tip" title="Directly studied, with clinical relevance">Directly Studied</span></td><td>The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.</td><td class="text-sm-center"><a class="btn btn-sm btn-outline-secondary" href="/pharmaco/genomics/DBSNPE000263">Details</a></td></tr><tr><td><strong>HLA class II histocompatibility antigen, DQ beta 1 chain</strong></td><td>HLA-DQB1*02:02</td><td><span class='not-available'>Not Available</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item">HLA-DQB1*02</span></span></span></td><td><span class="label label-danger basic-tip" title="SNP-Mediated Adverse Drug Reaction">ADR</span> <span class="label label-success basic-tip" title="Directly studied, with clinical relevance">Directly Studied</span></td><td>The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.</td><td class="text-sm-center"><a class="btn btn-sm btn-outline-secondary" href="/pharmaco/genomics/DBSNPE000264">Details</a></td></tr><tr><td><strong>Tenascin-X</strong></td><td><span class='not-available'>---</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item">(C;C)</span><span class='list-separator'> / </span><span class="separated-list-item">(C;T)</span></span></span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs12153855">T > C</a></span></span></span></td><td><span class="label label-danger basic-tip" title="SNP-Mediated Adverse Drug Reaction">ADR</span> <span class="label label-success basic-tip" title="Directly studied, with clinical relevance">Directly Studied</span></td><td>The presence of this polymorphism in TNXB may indicate an increased risk of drug-induced ALT-elevations leading to hepatotoxicity when treated with lapatinib.</td><td class="text-sm-center"><a class="btn btn-sm btn-outline-secondary" href="/pharmaco/genomics/DBSNPE000265">Details</a></td></tr></tbody></table></dd></dl><h2 id="interactions" class="section-header">Interactions</h2><dl><dt class="col-md-2 col-sm-4">Drug Interactions <a tabindex="0" role="button" data-toggle="popover" data-content="Drug-drug interactions extracted from drug labels and scientific publications. The commercial version includes severity and basis for interaction. &mdash; <a target=&quot;_blank&quot; href=&quot;https://drugbankplus.com/scientific&quot;>Learn More</a>" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);"><div class="drugbank-icon icon-information"><svg class="icon" role="img" title="information"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#information"> </use></svg></div></a></dt><dd class="col-md-10 col-sm-8"><div class="alert alert-danger">This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. </div><ul class="nav nav-tabs drug-interaction-tabs"><li class="interactions index nav-item"><a class="toggle-row-display nav-link active" data-source="/drugs/DB01259/drug_interactions.json" href="#show-all">All Drugs</a></li><li class="interactions approved nav-item"><a class="toggle-row-display nav-link" data-source="/drugs/DB01259/drug_interactions.json?group=approved" href="#show-approved">Approved</a></li><li class="interactions approved nav-item"><a class="toggle-row-display nav-link" data-source="/drugs/DB01259/drug_interactions.json?group=vet_approved" href="#show-vet_approved">Vet approved</a></li><li class="interactions approved nav-item"><a class="toggle-row-display nav-link" data-source="/drugs/DB01259/drug_interactions.json?group=nutraceutical" href="#show-nutraceutical">Nutraceutical</a></li><li class="interactions approved nav-item"><a class="toggle-row-display nav-link" data-source="/drugs/DB01259/drug_interactions.json?group=illicit" href="#show-illicit">Illicit</a></li><li class="interactions approved nav-item"><a class="toggle-row-display nav-link" data-source="/drugs/DB01259/drug_interactions.json?group=withdrawn" href="#show-withdrawn">Withdrawn</a></li><li class="interactions approved nav-item"><a class="toggle-row-display nav-link" data-source="/drugs/DB01259/drug_interactions.json?group=investigational" href="#show-investigational">Investigational</a></li><li class="interactions approved nav-item"><a class="toggle-row-display nav-link" data-source="/drugs/DB01259/drug_interactions.json?group=experimental" href="#show-experimental">Experimental</a></li></ul><div class="drug-interaction-table has-locked-content"><table class="table table-sm dt-responsive datatable-remote" data-source="/drugs/DB01259/drug_interactions.json" data-total="888" id="drug-interactions" style="width: 100%"><thead><tr><th class="head-sm">Drug</th><th>Interaction</th></tr><tr class="unlock-row"><th class="no-sort" colspan="2"><div class="locked-link" data-field="ddi" data-target="#locked-modal" data-toggle="modal"><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div> Unlock Additional Data</div></th></tr></thead><tbody><tr><td><a href="/drugs/DB08496">(R)-warfarin</a></td><td>The serum concentration of (R)-warfarin can be increased when it is combined with Lapatinib.</td></tr><tr><td><a href="/drugs/DB14055">(S)-Warfarin</a></td><td>The serum concentration of (S)-Warfarin can be increased when it is combined with Lapatinib.</td></tr><tr><td><a href="/drugs/DB12629">3,5-diiodothyropropionic acid</a></td><td>The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Lapatinib.</td></tr><tr><td><a href="/drugs/DB03374">3,5-Diiodotyrosine</a></td><td>The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Lapatinib.</td></tr><tr><td><a href="/drugs/DB03410">4-hydroxycoumarin</a></td><td>The metabolism of 4-hydroxycoumarin can be decreased when combined with Lapatinib.</td></tr><tr><td><a href="/drugs/DB12515">9-aminocamptothecin</a></td><td>The metabolism of 9-aminocamptothecin can be decreased when combined with Lapatinib.</td></tr><tr><td><a href="/drugs/DB05084">Abaloparatide</a></td><td>The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Lapatinib.</td></tr><tr><td><a href="/drugs/DB01281">Abatacept</a></td><td>The metabolism of Lapatinib can be increased when combined with Abatacept.</td></tr><tr><td><a href="/drugs/DB12565">Abexinostat</a></td><td>The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Abexinostat.</td></tr><tr><td><a href="/drugs/DB05812">Abiraterone</a></td><td>The metabolism of Lapatinib can be decreased when combined with Abiraterone.</td></tr></tbody></table><div class="locked-fields-holder" data-for="#drug-interactions"><div class="locked-fields closed" data-collapsed="collapsed"><div class="locked-tab"><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div><span class="tab-label">Additional Data Available</span><div class="drugbank-icon icon-arrow-left"><svg class="icon" role="img" title="arrow-left"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#arrow-left"> </use></svg></div><div class="drugbank-icon icon-arrow-right"><svg class="icon" role="img" title="arrow-right"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#arrow-right"> </use></svg></div></div><ul class="locked-accordion"><div class="flex-content"><li class="closed"><div class="flex-content"><div class="locked-header">Extended Description <div class="drugbank-icon icon-plus"><svg class="icon" role="img" title="plus"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#plus"> </use></svg></div></div><div class="locked-content"><div class="locked-info"><div class="close-tab drugbank-icon icon-exit"><svg class="icon" role="img" title="exit"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#exit"> </use></svg></div><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div><div class="locked-panel-header">Extended Description</div><p>Extended description of the mechanism of action and particular properties of each drug interaction.</p><a class="btn btn-sm btn-pink track-link" target="_blank" data-link-id="locked/ddi-extended-description" href="https://drugbankplus.com/scientific">Learn more</a></div></div></div></li><li class="closed"><div class="flex-content"><div class="locked-header">Severity <div class="drugbank-icon icon-plus"><svg class="icon" role="img" title="plus"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#plus"> </use></svg></div></div><div class="locked-content"><div class="locked-info"><div class="close-tab drugbank-icon icon-exit"><svg class="icon" role="img" title="exit"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#exit"> </use></svg></div><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div><div class="locked-panel-header">Severity</div><p>A severity rating for each drug interaction, from minor to major.</p><a class="btn btn-sm btn-pink track-link" target="_blank" data-link-id="locked/ddi-severity" href="https://drugbankplus.com/scientific">Learn more</a></div></div></div></li><li class="closed"><div class="flex-content"><div class="locked-header">Evidence Level <div class="drugbank-icon icon-plus"><svg class="icon" role="img" title="plus"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#plus"> </use></svg></div></div><div class="locked-content"><div class="locked-info"><div class="close-tab drugbank-icon icon-exit"><svg class="icon" role="img" title="exit"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#exit"> </use></svg></div><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div><div class="locked-panel-header">Evidence Level</div><p>A rating for the strength of the evidence supporting each drug interaction.</p><a class="btn btn-sm btn-pink track-link" target="_blank" data-link-id="locked/ddi-evidence-level" href="https://drugbankplus.com/scientific">Learn more</a></div></div></div></li><li class="closed"><div class="flex-content"><div class="locked-header">Action <div class="drugbank-icon icon-plus"><svg class="icon" role="img" title="plus"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#plus"> </use></svg></div></div><div class="locked-content"><div class="locked-info"><div class="close-tab drugbank-icon icon-exit"><svg class="icon" role="img" title="exit"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#exit"> </use></svg></div><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div><div class="locked-panel-header">Action</div><p>An effect category for each drug interaction. Know how this interaction affects the subject drug.</p><a class="btn btn-sm btn-pink track-link" target="_blank" data-link-id="locked/ddi-action" href="https://drugbankplus.com/scientific">Learn more</a></div></div></div></li></div></ul></div></div></div></dd><dt class="col-md-2 col-sm-4">Food Interactions</dt><dd class="col-md-10 col-sm-8"><ul class="list-unstyled table-list"><li>Avoid grapefruit products. Grapefruit may reduce the CYP3A4 metabolism of lapatinib, increasing its serum levels.</li>
<li>Take separate from meals. Take lapatinib at least 1 hour before or after eating, as lapatinib bioavailability is elevated by food.</li></ul></dd></dl><h2 id="references" class="section-header">References</h2><dl><dt class="col-md-2 col-sm-4">Synthesis Reference</dt><dd class="col-md-10 col-sm-8"><a target="_blank" rel="noopener" href="https://www.google.com/?tbm=pts#q=6727256&amp;tbm=pts">US6727256</a></dd><dt class="col-md-2 col-sm-4">General References</dt><dd class="col-md-10 col-sm-8"><ol class="cite-this-references"><li id="reference-A2248">Nelson MH, Dolder CR: Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother. 2006 Feb;40(2):261-9. Epub 2006 Jan 17. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/16418322">PubMed:16418322</a>] </li><li id="reference-A2249">Burris HA 3rd: Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9 Suppl 3:10-5. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/15163842">PubMed:15163842</a>] </li><li id="reference-A2250">Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005 Aug 10;23(23):5305-13. Epub 2005 Jun 13. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/15955900">PubMed:15955900</a>] </li><li id="reference-A2251">Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/17192538">PubMed:17192538</a>] </li><li id="reference-A2252">Johnston SR, Leary A: Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc). 2006 Jul;42(7):441-53. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/16894399">PubMed:16894399</a>] </li><li id="reference-A2253">Tevaarwerk AJ, Kolesar JM: Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009;31 Pt 2:2332-48. doi: 10.1016/j.clinthera.2009.11.029. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20110044">PubMed:20110044</a>] </li><li id="reference-A2254">Medina PJ, Goodin S: Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18803986">PubMed:18803986</a>] </li></ol></dd><dt class="col-md-2 col-sm-4">External Links</dt><dd class="col-md-10 col-sm-8"><dl><dt class="col-md-4 col-sm-5">Human Metabolome Database</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.hmdb.ca/metabolites/HMDB0015388">HMDB0015388</a></dd><dt class="col-md-4 col-sm-5">KEGG Drug</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.genome.jp/dbget-bin/www_bget?drug:D04024">D04024</a></dd><dt class="col-md-4 col-sm-5">PubChem Compound</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=208908">208908</a></dd><dt class="col-md-4 col-sm-5">PubChem Substance</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46507141">46507141</a></dd><dt class="col-md-4 col-sm-5">ChemSpider</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.chemspider.com/Chemical-Structure.181006.html">181006</a></dd><dt class="col-md-4 col-sm-5">BindingDB</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=5445">5445</a></dd><dt class="col-md-4 col-sm-5">RxNav</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&amp;searchTerm=480167">480167</a></dd><dt class="col-md-4 col-sm-5">ChEBI</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=49603">49603</a></dd><dt class="col-md-4 col-sm-5">ChEMBL</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL554">CHEMBL554</a></dd><dt class="col-md-4 col-sm-5">ZINC</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="https://zinc.docking.org/substances/ZINC000001550477">ZINC000001550477</a></dd><dt class="col-md-4 col-sm-5">Therapeutic Targets Database</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DCL000344">DCL000344</a></dd><dt class="col-md-4 col-sm-5">PharmGKB</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.pharmgkb.org/drug/PA152241907">PA152241907</a></dd><dt class="col-md-4 col-sm-5">PDBe Ligand</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/FMM">FMM</a></dd><dt class="col-md-4 col-sm-5">RxList</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.rxlist.com/cgi/generic/tykerb.htm">RxList Drug Page</a></dd><dt class="col-md-4 col-sm-5">Drugs.com</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://www.drugs.com/cdi/lapatinib.html">Drugs.com Drug Page</a></dd><dt class="col-md-4 col-sm-5">Wikipedia</dt><dd class="col-md-8 col-sm-7"><a target="_blank" rel="noopener" href="http://en.wikipedia.org/wiki/Lapatinib">Lapatinib</a></dd></dl></dd><dt class="col-md-2 col-sm-4">ATC Codes</dt><dd class="col-md-10 col-sm-8"><a data-no-turbolink="true" href="/atc/L01XE07">L01XE07 &mdash; Lapatinib</a><ul class="atc-drug-tree"><li><a data-no-turbolink="true" href="/atc/L01XE">L01XE &mdash; Protein kinase inhibitors</a></li><li><a data-no-turbolink="true" href="/atc/L01X">L01X &mdash; OTHER ANTINEOPLASTIC AGENTS</a></li><li><a data-no-turbolink="true" href="/atc/L01">L01 &mdash; ANTINEOPLASTIC AGENTS</a></li><li><a data-no-turbolink="true" href="/atc/L">L &mdash; ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</a></li></ul></dd><dt class="col-md-2 col-sm-4">AHFS Codes</dt><dd class="col-md-10 col-sm-8"><ul class="list-unstyled table-list"><li>10:00.00 &mdash; Antineoplastic Agents</li></ul></dd><dt class="col-md-2 col-sm-4">PDB Entries</dt><dd class="col-md-10 col-sm-8"><span class="inline-separated-list-container"><span class="simple-separated-list-item"><a target="_blank" rel="noopener" href="http://www.rcsb.org/pdb/explore.do?structureId=1xkk">1xkk</a></span><span class='list-separator'> / </span><span class="simple-separated-list-item"><a target="_blank" rel="noopener" href="http://www.rcsb.org/pdb/explore.do?structureId=3bbt">3bbt</a></span></span></dd></dl><h2 id="clinical-trials" class="section-header">Clinical Trials</h2><dl><dt class="col-md-2 col-sm-4">Clinical Trials <a tabindex="0" role="button" data-toggle="popover" data-content="Clinical trial data extracted from government clinical trial databases. The commercial version includes title, phase, status, dates, and conditions with associated ICD10 or MedDRA identifiers. &mdash; <a target=&quot;_blank&quot; href=&quot;https://drugbankplus.com/scientific&quot;>Learn More</a>" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);"><div class="drugbank-icon icon-information"><svg class="icon" role="img" title="information"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#information"> </use></svg></div></a></dt><dd class="col-md-10 col-sm-8"><table class="clinical-trials table table-sm datatable dt-responsive" style="width: 100%"><thead><th>Phase</th><th>Status</th><th>Purpose</th><th>Conditions</th><th>Count</th></thead><tbody><tr><td>0</td><td>Completed</td><td>Basic Science</td><td><a href="/indications/DBCOND0047327">Acoustic Schwannoma</a> <span>/</span> <a href="/indications/DBCOND0042839">Auditory Tumor</a> <span>/</span> <a href="/indications/DBCOND0002377">Neurofibromatosis 2</a> <span>/</span> <a href="/indications/DBCOND0042838">NF2</a> <span>/</span> <a href="/indications/DBCOND0064420">Vestibular Schwannomas</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0047327%2CDBCOND0042839%2CDBCOND0002377%2CDBCOND0042838%2CDBCOND0064420&amp;phase=0&amp;purpose=basic_science&amp;status=completed">1</a></td></tr><tr><td>0</td><td>Completed</td><td>Diagnostic</td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201&amp;phase=0&amp;purpose=diagnostic&amp;status=completed">1</a></td></tr><tr><td>0</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=0&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>0</td><td>Terminated</td><td><span class='not-available'>Not Available</span></td><td><a href="/indications/DBCOND0036971">Bladder Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0036622">Cystectomy</a> <span>/</span> <a href="/indications/DBCOND0049893">Infiltrative Bladder Carcinoma</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0036971%2CDBCOND0036622%2CDBCOND0049893&amp;phase=0&amp;status=terminated">1</a></td></tr><tr><td>0</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0054292">Epithelial Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0054292&amp;phase=0&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0052373">Anaplastic Astrocytoma (AA)</a> <span>/</span> <a href="/indications/DBCOND0033927">Anaplastic Ependymoma</a> <span>/</span> <a href="/indications/DBCOND0052374">Anaplastic Oligodendroglioma (AO)</a> <span>/</span> <a href="/indications/DBCOND0002894">Gliosarcoma</a> <span>/</span> <a href="/indications/DBCOND0028957">Mixed Gliomas</a> <span>/</span> <a href="/indications/DBCOND0034088">Recurrent Adult Brain Neoplasm</a> <span>/</span> <a href="/indications/DBCOND0033792">Recurrent Glioblastoma</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0052373%2CDBCOND0033927%2CDBCOND0052374%2CDBCOND0002894%2CDBCOND0028957%2CDBCOND0034088%2CDBCOND0033792&amp;phase=1&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>1</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0041606">Cancer, Advanced</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0041606&amp;phase=1&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>1</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0060946">Central Nervous System (CNS) Metastases</a> <span>/</span> <a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0060946%2CDBCOND0030200&amp;phase=1&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>1</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0090726">Metastatic Thyroid Gland Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0086964">Unresectable Thyroid Gland Carcinoma</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0090726%2CDBCOND0086964&amp;phase=1&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Other</td><td><a href="/indications/DBCOND0042471">Advanced or Metastatic ErbB2-overexpressing Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0042471%2CDBCOND0030201&amp;phase=1&amp;purpose=other&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Other</td><td><a href="/indications/DBCOND0034613">Malignancies</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0034613&amp;phase=1&amp;purpose=other&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0033079">Advanced Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0033079&amp;phase=1&amp;purpose=treatment&amp;status=completed">2</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0034287">Advanced Colorectal Cancer</a> <span>/</span> <a href="/indications/DBCOND0039029">Metastatic Colorectal Cancer (MCRC)</a> <span>/</span> <a href="/indications/DBCOND0036298">Neoplasms, Colorectal</a> <span>/</span> <a href="/indications/DBCOND0038498">Responsive to Fluoropyrimidines</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0034287%2CDBCOND0039029%2CDBCOND0036298%2CDBCOND0038498&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0030815">Advanced Non Small Cell Lung Cancer</a> <span>/</span> <a href="/indications/DBCOND0046916">Lung Cancer Non-Small Cell Cancer (NSCLC)</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030815%2CDBCOND0046916&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0042471">Advanced or Metastatic ErbB2-overexpressing Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0042471%2CDBCOND0030201&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0056318">Anemia of Chronic Kidney Disease</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0056318&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028448">Brain and Central Nervous System Tumors</a> <span>/</span> <a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0092003">Cancer, Bladder</a> <span>/</span> <a href="/indications/DBCOND0045726">Esophageal Cancers</a> <span>/</span> <a href="/indications/DBCOND0028464">Extragonadal Germ Cell Tumor</a> <span>/</span> <a href="/indications/DBCOND0072929">Lung Cancers</a> <span>/</span> <a href="/indications/DBCOND0045917">Malignant Neoplasm of Stomach</a> <span>/</span> <a href="/indications/DBCOND0028213">Ovarian Cancer</a> <span>/</span> <a href="/indications/DBCOND0062462">Prostate Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028448%2CDBCOND0028036%2CDBCOND0092003%2CDBCOND0045726%2CDBCOND0028464%2CDBCOND0072929%2CDBCOND0045917%2CDBCOND0028213%2CDBCOND0062462&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=1&amp;purpose=treatment&amp;status=completed">7</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0034653">Locally Recurrent and Metastatic Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0034613">Malignancies</a> <span>/</span> <a href="/indications/DBCOND0027674">Metastases</a> <span>/</span> <a href="/indications/DBCOND0060442">Metastatic Cancers</a> <span>/</span> <a href="/indications/DBCOND0030201">Neoplasms, Breast</a> <span>/</span> <a href="/indications/DBCOND0029318">Oncology</a> <span>/</span> <a href="/indications/DBCOND0029621">Tumors</a> <span>/</span> <a href="/indications/DBCOND0041388">Tumors, Breast</a> <span>/</span> <a href="/indications/DBCOND0074335">Tumors, Solid</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036%2CDBCOND0034653%2CDBCOND0034613%2CDBCOND0027674%2CDBCOND0060442%2CDBCOND0030201%2CDBCOND0029318%2CDBCOND0029621%2CDBCOND0041388%2CDBCOND0074335&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0060442">Metastatic Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036%2CDBCOND0060442&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0039964">Metastatic ErbB2</a> <span>/</span> <a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036%2CDBCOND0039964%2CDBCOND0030201&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036%2CDBCOND0030201&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0029875">Tumors Metastatic to Brain</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036%2CDBCOND0029875&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0092003">Cancer, Bladder</a> <span>/</span> <a href="/indications/DBCOND0028512">Transitional Cell Cancer of the Renal Pelvis and Ureter</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0092003%2CDBCOND0028512&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0063246">Colorectal Cancers</a> <span>/</span> <a href="/indications/DBCOND0050085">Head and Neck Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0072929">Lung Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0063246%2CDBCOND0050085%2CDBCOND0072929&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0051050">HER-2 Gene Amplification</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0051050&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0066412">HER2 Positive Breast Cancers</a> <span>/</span> <a href="/indications/DBCOND0028546">Male Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028640">Recurrent Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028549">Stage IIIB Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028641">Stage IIIC Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028550">Stage IV Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028453">Unspecified Adult Solid Tumor, Protocol Specific</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0066412%2CDBCOND0028546%2CDBCOND0028640%2CDBCOND0028549%2CDBCOND0028641%2CDBCOND0028550%2CDBCOND0028453&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0040154">HER2 Positive</a> <span>/</span> <a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0029875">Tumors Metastatic to Brain</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0040154%2CDBCOND0030200%2CDBCOND0029875&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0037939">HER2/Neu Positive</a> <span>/</span> <a href="/indications/DBCOND0031787">Invasive Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0030216">Recurrent Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0028550">Stage IV Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0092437">Stage IV Breast Cancer AJCC v6 and v7</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0037939%2CDBCOND0031787%2CDBCOND0030216%2CDBCOND0028550%2CDBCOND0092437&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0034432">Locally Advanced Breast Cancer (LABC)</a> <span>/</span> <a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0034432%2CDBCOND0030200&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0034613">Malignancies</a> <span>/</span> <a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0034613%2CDBCOND0030201&amp;phase=1&amp;purpose=treatment&amp;status=completed">2</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0034613">Malignancies</a> <span>/</span> <a href="/indications/DBCOND0055462">Renal Cell Adenocarcinoma</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0034613%2CDBCOND0055462&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0046362">Malignant Lymphomas</a> <span>/</span> <a href="/indications/DBCOND0028453">Unspecified Adult Solid Tumor, Protocol Specific</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0046362%2CDBCOND0028453&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030200&amp;phase=1&amp;purpose=treatment&amp;status=completed">2</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201&amp;phase=1&amp;purpose=treatment&amp;status=completed">5</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a> <span>/</span> <a href="/indications/DBCOND0049025">Solid Tumor Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201%2CDBCOND0049025&amp;phase=1&amp;purpose=treatment&amp;status=completed">2</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0055462">Renal Cell Adenocarcinoma</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0055462&amp;phase=1&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0074335">Tumors, Solid</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0074335&amp;phase=1&amp;purpose=treatment&amp;status=completed">2</a></td></tr><tr><td>1</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028453">Unspecified Adult Solid Tumor, Protocol Specific</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028453&amp;phase=1&amp;purpose=treatment&amp;status=completed">2</a></td></tr><tr><td>1</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0032762">Adenocarcinomas of the Gastroesophageal Junction</a> <span>/</span> <a href="/indications/DBCOND0036667">Advanced Gastric Cancer</a> <span>/</span> <a href="/indications/DBCOND0066412">HER2 Positive Breast Cancers</a> <span>/</span> <a href="/indications/DBCOND0028546">Male Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028640">Recurrent Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028797">Recurrent Esophageal Cancer</a> <span>/</span> <a href="/indications/DBCOND0028800">Recurrent Gastric Cancer</a> <span>/</span> <a href="/indications/DBCOND0028641">Stage IIIC Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0048770">Stage IIIC Esophageal Cancer</a> <span>/</span> <a href="/indications/DBCOND0030369">Stage IIIC Gastric Cancer</a> <span>/</span> <a href="/indications/DBCOND0028550">Stage IV Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028762">Stage IV Esophageal Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0032762%2CDBCOND0036667%2CDBCOND0066412%2CDBCOND0028546%2CDBCOND0028640%2CDBCOND0028797%2CDBCOND0028800%2CDBCOND0028641%2CDBCOND0048770%2CDBCOND0030369%2CDBCOND0028550%2CDBCOND0028762&amp;phase=1&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0030110">Advanced Solid Tumors</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030110&amp;phase=1&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0030110">Advanced Solid Tumors</a> <span>/</span> <a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030110%2CDBCOND0028036&amp;phase=1&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=1&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0036417">Estrogen Receptor Negative</a> <span>/</span> <a href="/indications/DBCOND0031389">Estrogen Receptor Positive</a> <span>/</span> <a href="/indications/DBCOND0037939">HER2/Neu Positive</a> <span>/</span> <a href="/indications/DBCOND0038639">Progesterone Receptor Negative</a> <span>/</span> <a href="/indications/DBCOND0031390">Progesterone Receptor Positive</a> <span>/</span> <a href="/indications/DBCOND0030216">Recurrent Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0028550">Stage IV Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0036417%2CDBCOND0031389%2CDBCOND0037939%2CDBCOND0038639%2CDBCOND0031390%2CDBCOND0030216%2CDBCOND0028550&amp;phase=1&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0049718">Failure or Contraindication of Trastuzumab Therapy</a> <span>/</span> <a href="/indications/DBCOND0049717">First or Second Line Therapy</a> <span>/</span> <a href="/indications/DBCOND0040154">HER2 Positive</a> <span>/</span> <a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0049718%2CDBCOND0049717%2CDBCOND0040154%2CDBCOND0030200&amp;phase=1&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0066412">HER2 Positive Breast Cancers</a> <span>/</span> <a href="/indications/DBCOND0053519">Malignant Neoplasm of Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0066412%2CDBCOND0053519&amp;phase=1&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0039748">Locally Advanced or Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0039748&amp;phase=1&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0028213">Ovarian Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028213&amp;phase=1&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0028453">Unspecified Adult Solid Tumor, Protocol Specific</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028453&amp;phase=1&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1</td><td>Unknown Status</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=1&amp;purpose=treatment&amp;status=unknown_status">1</a></td></tr><tr><td>1</td><td>Unknown Status</td><td>Treatment</td><td><a href="/indications/DBCOND0054384">Recurrent Endometrial Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0054384&amp;phase=1&amp;purpose=treatment&amp;status=unknown_status">1</a></td></tr><tr><td>1</td><td>Withdrawn</td><td><span class='not-available'>Not Available</span></td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=1&amp;status=withdrawn">1</a></td></tr><tr><td>1</td><td>Withdrawn</td><td>Treatment</td><td><a href="/indications/DBCOND0030110">Advanced Solid Tumors</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030110&amp;phase=1&amp;purpose=treatment&amp;status=withdrawn">1</a></td></tr><tr><td>1</td><td>Withdrawn</td><td>Treatment</td><td><a href="/indications/DBCOND0028122">Healthy Volunteers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028122&amp;phase=1&amp;purpose=treatment&amp;status=withdrawn">1</a></td></tr><tr><td>1, 2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0030660">Central Nervous System Metastases</a> <span>/</span> <a href="/indications/DBCOND0066412">HER2 Positive Breast Cancers</a> <span>/</span> <a href="/indications/DBCOND0028546">Male Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028640">Recurrent Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028550">Stage IV Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030660%2CDBCOND0066412%2CDBCOND0028546%2CDBCOND0028640%2CDBCOND0028550&amp;phase=1%2C2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>1, 2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0067354">HER2 Positive Metastatic Breast Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0067354&amp;phase=1%2C2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>1, 2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201&amp;phase=1%2C2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>1, 2</td><td>Completed</td><td><span class='not-available'>Not Available</span></td><td><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030200&amp;phase=1%2C2&amp;status=completed">1</a></td></tr><tr><td>1, 2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028448">Brain and Central Nervous System Tumors</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028448&amp;phase=1%2C2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1, 2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=1%2C2&amp;purpose=treatment&amp;status=completed">4</a></td></tr><tr><td>1, 2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0050085">Head and Neck Carcinoma</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0050085&amp;phase=1%2C2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1, 2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030200&amp;phase=1%2C2&amp;purpose=treatment&amp;status=completed">2</a></td></tr><tr><td>1, 2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0035169">Ovarian Epithelial Cancer Stage III</a> <span>/</span> <a href="/indications/DBCOND0028550">Stage IV Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0030167">Stage IV Ovarian Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0035169%2CDBCOND0028550%2CDBCOND0030167&amp;phase=1%2C2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1, 2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0031172">Recurrent Childhood Anaplastic Astrocytoma</a> <span>/</span> <a href="/indications/DBCOND0029294">Recurrent Childhood Brain Stem Glioma</a> <span>/</span> <a href="/indications/DBCOND0028750">Recurrent Childhood Ependymoma</a> <span>/</span> <a href="/indications/DBCOND0031173">Recurrent Childhood Giant Cell Glioblastoma</a> <span>/</span> <a href="/indications/DBCOND0031174">Recurrent Childhood Glioblastoma</a> <span>/</span> <a href="/indications/DBCOND0031175">Recurrent Childhood Gliosarcoma</a> <span>/</span> <a href="/indications/DBCOND0028751">Recurrent Childhood Medulloblastoma</a> <span>/</span> <a href="/indications/DBCOND0031176">Recurrent Childhood Oligodendroglioma</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0031172%2CDBCOND0029294%2CDBCOND0028750%2CDBCOND0031173%2CDBCOND0031174%2CDBCOND0031175%2CDBCOND0028751%2CDBCOND0031176&amp;phase=1%2C2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>1, 2</td><td>Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0063246">Colorectal Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0063246&amp;phase=1%2C2&amp;purpose=treatment&amp;status=recruiting">1</a></td></tr><tr><td>1, 2</td><td>Suspended</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=1%2C2&amp;purpose=treatment&amp;status=suspended">1</a></td></tr><tr><td>1, 2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0030040">Adenocarcinoma of the Esophagus</a> <span>/</span> <a href="/indications/DBCOND0032762">Adenocarcinomas of the Gastroesophageal Junction</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030040%2CDBCOND0032762&amp;phase=1%2C2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1, 2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0066909">Neoplasms Metastasis</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036%2CDBCOND0066909&amp;phase=1%2C2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1, 2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0067354">HER2 Positive Metastatic Breast Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0067354&amp;phase=1%2C2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1, 2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030200&amp;phase=1%2C2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>1, 2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0062462">Prostate Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0062462&amp;phase=1%2C2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=2&amp;purpose=treatment&amp;status=active_not_recruiting">2</a></td></tr><tr><td>2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0050808">Geriatric Health Services</a> <span>/</span> <a href="/indications/DBCOND0037939">HER2/Neu Positive</a> <span>/</span> <a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0050808%2CDBCOND0037939%2CDBCOND0030201&amp;phase=2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0066412">HER2 Positive Breast Cancers</a> <span>/</span> <a href="/indications/DBCOND0028640">Recurrent Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028550">Stage IV Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0066412%2CDBCOND0028640%2CDBCOND0028550&amp;phase=2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0029216">HER2 Positive Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0031787">Invasive Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0039896">Metastatic Malignant Neoplasm in the Brain</a> <span>/</span> <a href="/indications/DBCOND0030216">Recurrent Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0092437">Stage IV Breast Cancer AJCC v6 and v7</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0029216%2CDBCOND0031787%2CDBCOND0039896%2CDBCOND0030216%2CDBCOND0092437&amp;phase=2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0050085">Head and Neck Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0043488">Squamous Cell Carcinoma (SCC)</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0050085%2CDBCOND0043488&amp;phase=2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0050085">Head and Neck Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0035874">Squamous Cell Carcinoma of the Head and Neck (SCCHN)</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0050085%2CDBCOND0035874&amp;phase=2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0046916">Lung Cancer Non-Small Cell Cancer (NSCLC)</a> <span>/</span> <a href="/indications/DBCOND0048944">Small Cell Lung Cancer (SCLC)</a> <span>/</span> <a href="/indications/DBCOND0028663">Thymic Carcinoma</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0046916%2CDBCOND0048944%2CDBCOND0028663&amp;phase=2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030200&amp;phase=2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0065924">Metastatic Breast Cancer With Intracranial Metastases</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0065924&amp;phase=2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0039029">Metastatic Colorectal Cancer (MCRC)</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0039029&amp;phase=2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201&amp;phase=2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0059994">Non-HPV Locally Advanced Head and Neck Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0059994&amp;phase=2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>2</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0061655">Reccurent/Metastatic Solid Tumor Disease</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0061655&amp;phase=2&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0050451">70 Years Old Patients and Over</a> <span>/</span> <a href="/indications/DBCOND0050452">After One Line of Chemotherapy With Trastuzumab</a> <span>/</span> <a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0050451%2CDBCOND0050452%2CDBCOND0030200&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0060431">Adenocarcinomas</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0060431&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0029159">Adult Primary Hepatocellular Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0028828">Advanced Adult Primary Liver Cancer</a> <span>/</span> <a href="/indications/DBCOND0028838">Localized Unresectable Adult Primary Liver Cancer</a> <span>/</span> <a href="/indications/DBCOND0028856">Recurrent Adult Primary Liver Cancer</a> <span>/</span> <a href="/indications/DBCOND0028798">Recurrent Extrahepatic Bile Duct Cancer</a> <span>/</span> <a href="/indications/DBCOND0028799">Recurrent Gallbladder Cancer</a> <span>/</span> <a href="/indications/DBCOND0028791">Unresectable Extrahepatic Bile Duct Cancer</a> <span>/</span> <a href="/indications/DBCOND0028792">Unresectable Gallbladder Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0029159%2CDBCOND0028828%2CDBCOND0028838%2CDBCOND0028856%2CDBCOND0028798%2CDBCOND0028799%2CDBCOND0028791%2CDBCOND0028792&amp;phase=2&amp;purpose=treatment&amp;status=completed">2</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0031019">Advanced Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0031019%2CDBCOND0028036&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0036667">Advanced Gastric Cancer</a> <span>/</span> <a href="/indications/DBCOND0029648">Diffuse Adenocarcinoma of the Stomach</a> <span>/</span> <a href="/indications/DBCOND0029650">Intestinal Adenocarcinoma of the Stomach</a> <span>/</span> <a href="/indications/DBCOND0029651">Mixed Adenocarcinoma of the Stomach</a> <span>/</span> <a href="/indications/DBCOND0028800">Recurrent Gastric Cancer</a> <span>/</span> <a href="/indications/DBCOND0028835">Stage III Gastric Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0036667%2CDBCOND0029648%2CDBCOND0029650%2CDBCOND0029651%2CDBCOND0028800%2CDBCOND0028835&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0046085">BRMS1</a> <span>/</span> <a href="/indications/DBCOND0046087">Patient With a Maximum of One Chemotherapy</a> <span>/</span> <a href="/indications/DBCOND0046088">Patient With Progression After Taxanes</a> <span>/</span> <a href="/indications/DBCOND0046086">Performance Status Zero to Two for Beginning the Study</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0046085%2CDBCOND0046087%2CDBCOND0046088%2CDBCOND0046086&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028268">Brain Cancer</a> <span>/</span> <a href="/indications/DBCOND0037448">Pediatric Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028268%2CDBCOND0037448&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=2&amp;purpose=treatment&amp;status=completed">13</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028520">Cardiac Toxicity</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036%2CDBCOND0028520&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0030645">ErbB1 Expressing</a> <span>/</span> <a href="/indications/DBCOND0030644">ErbB2 Overexpressing</a> <span>/</span> <a href="/indications/DBCOND0030646">Inflammatory</a> <span>/</span> <a href="/indications/DBCOND0030201">Neoplasms, Breast</a> <span>/</span> <a href="/indications/DBCOND0030643">Newly Diagnosed</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036%2CDBCOND0030645%2CDBCOND0030644%2CDBCOND0030646%2CDBCOND0030201%2CDBCOND0030643&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036%2CDBCOND0030200&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0060442">Metastatic Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036%2CDBCOND0060442&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0030660">Central Nervous System Metastases</a> <span>/</span> <a href="/indications/DBCOND0066412">HER2 Positive Breast Cancers</a> <span>/</span> <a href="/indications/DBCOND0028546">Male Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028640">Recurrent Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028550">Stage IV Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0029875">Tumors Metastatic to Brain</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030660%2CDBCOND0066412%2CDBCOND0028546%2CDBCOND0028640%2CDBCOND0028550%2CDBCOND0029875&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0063246">Colorectal Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0063246&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0031389">Estrogen Receptor Positive</a> <span>/</span> <a href="/indications/DBCOND0030384">Male Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0031390">Progesterone Receptor Positive</a> <span>/</span> <a href="/indications/DBCOND0030216">Recurrent Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0028549">Stage IIIB Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028641">Stage IIIC Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028550">Stage IV Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0031389%2CDBCOND0030384%2CDBCOND0031390%2CDBCOND0030216%2CDBCOND0028549%2CDBCOND0028641%2CDBCOND0028550&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0030147">GBM</a> <span>/</span> <a href="/indications/DBCOND0046976">Glioblastoma Multiforme (GBM)</a> <span>/</span> <a href="/indications/DBCOND0032593">Gliomas</a> <span>/</span> <a href="/indications/DBCOND0002894">Gliosarcoma</a> <span>/</span> <a href="/indications/DBCOND0030776">GS</a> <span>/</span> <a href="/indications/DBCOND0054211">Neoplasms, Brain</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030147%2CDBCOND0046976%2CDBCOND0032593%2CDBCOND0002894%2CDBCOND0030776%2CDBCOND0054211&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0032593">Gliomas</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0032593&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0066412">HER2 Positive Breast Cancers</a> <span>/</span> <a href="/indications/DBCOND0029484">Stage II Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028774">Stage IIIA Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0066412%2CDBCOND0029484%2CDBCOND0028774&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0029216">HER2 Positive Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0037939">HER2/Neu Positive</a> <span>/</span> <a href="/indications/DBCOND0030216">Recurrent Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0028549">Stage IIIB Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0092287">Stage IIIB Breast Cancer AJCC v7</a> <span>/</span> <a href="/indications/DBCOND0028641">Stage IIIC Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0092288">Stage IIIC Breast Cancer AJCC v7</a> <span>/</span> <a href="/indications/DBCOND0028550">Stage IV Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0092437">Stage IV Breast Cancer AJCC v6 and v7</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0029216%2CDBCOND0037939%2CDBCOND0030216%2CDBCOND0028549%2CDBCOND0092287%2CDBCOND0028641%2CDBCOND0092288%2CDBCOND0028550%2CDBCOND0092437&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0063722">HER2-Positive Early Stage Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0063722&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0067919">HER2-positive Gastric Cancer Patients With Liver Metastasis</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0067919&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0074097">HER2-positive Refractory Advanced Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0074097&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0050085">Head and Neck Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0029496">Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0029502">Recurrent Metastatic Squamous Neck Cancer With Occult Primary</a> <span>/</span> <a href="/indications/DBCOND0028809">Recurrent Salivary Gland Cancer</a> <span>/</span> <a href="/indications/DBCOND0029504">Recurrent Squamous Cell Carcinoma of the Hypopharynx</a> <span>/</span> <a href="/indications/DBCOND0028811">Recurrent Squamous Cell Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0028812">Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0028814">Recurrent Squamous Cell Carcinoma of the Oropharynx</a> <span>/</span> <a href="/indications/DBCOND0029505">Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</a> <span>/</span> <a href="/indications/DBCOND0029506">Recurrent Verrucous Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0029507">Recurrent Verrucous Carcinoma of the Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0029844">Salivary Gland Squamous Cell Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0028780">Stage IV Salivary Gland Cancer</a> <span>/</span> <a href="/indications/DBCOND0029520">Stage IV Squamous Cell Carcinoma of the Hypopharynx</a> <span>/</span> <a href="/indications/DBCOND0028781">Stage IV Squamous Cell Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0028782">Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0028784">Stage IV Squamous Cell Carcinoma of the Oropharynx</a> <span>/</span> <a href="/indications/DBCOND0029521">Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</a> <span>/</span> <a href="/indications/DBCOND0029522">Stage IV Verrucous Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0029523">Stage IV Verrucous Carcinoma of the Oral Cavity</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0050085%2CDBCOND0029496%2CDBCOND0029502%2CDBCOND0028809%2CDBCOND0029504%2CDBCOND0028811%2CDBCOND0028812%2CDBCOND0028814%2CDBCOND0029505%2CDBCOND0029506%2CDBCOND0029507%2CDBCOND0029844%2CDBCOND0028780%2CDBCOND0029520%2CDBCOND0028781%2CDBCOND0028782%2CDBCOND0028784%2CDBCOND0029521%2CDBCOND0029522%2CDBCOND0029523&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0031156">High-grade Salivary Gland Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0031157">High-grade Salivary Gland Mucoepidermoid Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0031158">Low-grade Salivary Gland Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0031159">Low-grade Salivary Gland Mucoepidermoid Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0028854">Recurrent Adenoid Cystic Carcinoma of the Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0028809">Recurrent Salivary Gland Cancer</a> <span>/</span> <a href="/indications/DBCOND0031160">Salivary Gland Acinic Cell Tumor</a> <span>/</span> <a href="/indications/DBCOND0029654">Salivary Gland Adenocarcinoma</a> <span>/</span> <a href="/indications/DBCOND0030688">Salivary Gland Adenoid Cystic Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0031161">Salivary Gland Malignant Mixed Cell Type Tumor</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0031156%2CDBCOND0031157%2CDBCOND0031158%2CDBCOND0031159%2CDBCOND0028854%2CDBCOND0028809%2CDBCOND0031160%2CDBCOND0029654%2CDBCOND0030688%2CDBCOND0031161&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0032502">Lung Tumors</a> <span>/</span> <a href="/indications/DBCOND0029875">Tumors Metastatic to Brain</a> <span>/</span> <a href="/indications/DBCOND0041388">Tumors, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0032502%2CDBCOND0029875%2CDBCOND0041388&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0034613">Malignancies</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0034613&amp;phase=2&amp;purpose=treatment&amp;status=completed">2</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0087260">Malignant Neoplasm of Pancreas</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0087260&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030200&amp;phase=2&amp;purpose=treatment&amp;status=completed">2</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030200%2CDBCOND0030201&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0060442">Metastatic Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0060442&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0039029">Metastatic Colorectal Cancer (MCRC)</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0039029&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0030666">Metastatic Squamous Neck Cancer With Occult Primary</a> <span>/</span> <a href="/indications/DBCOND0029502">Recurrent Metastatic Squamous Neck Cancer With Occult Primary</a> <span>/</span> <a href="/indications/DBCOND0029504">Recurrent Squamous Cell Carcinoma of the Hypopharynx</a> <span>/</span> <a href="/indications/DBCOND0028811">Recurrent Squamous Cell Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0028812">Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0028813">Recurrent Squamous Cell Carcinoma of the Nasopharynx</a> <span>/</span> <a href="/indications/DBCOND0028814">Recurrent Squamous Cell Carcinoma of the Oropharynx</a> <span>/</span> <a href="/indications/DBCOND0029505">Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</a> <span>/</span> <a href="/indications/DBCOND0029844">Salivary Gland Squamous Cell Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0029520">Stage IV Squamous Cell Carcinoma of the Hypopharynx</a> <span>/</span> <a href="/indications/DBCOND0028781">Stage IV Squamous Cell Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0028782">Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0028783">Stage IV Squamous Cell Carcinoma of the Nasopharynx</a> <span>/</span> <a href="/indications/DBCOND0028784">Stage IV Squamous Cell Carcinoma of the Oropharynx</a> <span>/</span> <a href="/indications/DBCOND0029521">Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</a> <span>/</span> <a href="/indications/DBCOND0029524">Untreated Metastatic Squamous Neck Cancer With Occult Primary</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030666%2CDBCOND0029502%2CDBCOND0029504%2CDBCOND0028811%2CDBCOND0028812%2CDBCOND0028813%2CDBCOND0028814%2CDBCOND0029505%2CDBCOND0029844%2CDBCOND0029520%2CDBCOND0028781%2CDBCOND0028782%2CDBCOND0028783%2CDBCOND0028784%2CDBCOND0029521%2CDBCOND0029524&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0054211">Neoplasms, Brain</a> <span>/</span> <a href="/indications/DBCOND0042611">Spinal Cord Tumors</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0054211%2CDBCOND0042611&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201&amp;phase=2&amp;purpose=treatment&amp;status=completed">15</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0037762">Neoplasms, Gastrointestinal Tract</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0037762&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0036314">Neoplasms, Head and Neck</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0036314&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0036673">Neoplasms, Uterine Cervix</a> <span>/</span> <a href="/indications/DBCOND0025384">Recurrent, IV-B Cervical cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0036673%2CDBCOND0025384&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0002377">Neurofibromatosis 2</a> <span>/</span> <a href="/indications/DBCOND0064420">Vestibular Schwannomas</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0002377%2CDBCOND0064420&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028213">Ovarian Cancer</a> <span>/</span> <a href="/indications/DBCOND0028651">Peritoneal Cavity Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028213%2CDBCOND0028651&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0044903">Pituitary Adenomas</a> <span>/</span> <a href="/indications/DBCOND0037090">Prolactinomas</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0044903%2CDBCOND0037090&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028458">Primary Peritoneal Cavity Cancer</a> <span>/</span> <a href="/indications/DBCOND0028736">Recurrent Ovarian Epithelial Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028458%2CDBCOND0028736&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0062462">Prostate Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0062462&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028796">Recurrent Endometrial Carcinoma</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028796&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028658">Recurrent Prostate Cancer</a> <span>/</span> <a href="/indications/DBCOND0028877">Stage I Prostate Cancer</a> <span>/</span> <a href="/indications/DBCOND0028878">Stage IIA Prostate Cancer</a> <span>/</span> <a href="/indications/DBCOND0028879">Stage IIB Prostate Cancer</a> <span>/</span> <a href="/indications/DBCOND0028656">Stage III Prostate Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028658%2CDBCOND0028877%2CDBCOND0028878%2CDBCOND0028879%2CDBCOND0028656&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028658">Recurrent Prostate Cancer</a> <span>/</span> <a href="/indications/DBCOND0028657">Stage IV Prostate Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028658%2CDBCOND0028657&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028809">Recurrent Salivary Gland Cancer</a> <span>/</span> <a href="/indications/DBCOND0029504">Recurrent Squamous Cell Carcinoma of the Hypopharynx</a> <span>/</span> <a href="/indications/DBCOND0028811">Recurrent Squamous Cell Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0028812">Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0028813">Recurrent Squamous Cell Carcinoma of the Nasopharynx</a> <span>/</span> <a href="/indications/DBCOND0028814">Recurrent Squamous Cell Carcinoma of the Oropharynx</a> <span>/</span> <a href="/indications/DBCOND0029505">Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</a> <span>/</span> <a href="/indications/DBCOND0029506">Recurrent Verrucous Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0029507">Recurrent Verrucous Carcinoma of the Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0029844">Salivary Gland Squamous Cell Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0029520">Stage IV Squamous Cell Carcinoma of the Hypopharynx</a> <span>/</span> <a href="/indications/DBCOND0028783">Stage IV Squamous Cell Carcinoma of the Nasopharynx</a> <span>/</span> <a href="/indications/DBCOND0029845">Stage IVA Salivary Gland Cancer</a> <span>/</span> <a href="/indications/DBCOND0029846">Stage IVA Squamous Cell Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0029847">Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0029848">Stage IVA Squamous Cell Carcinoma of the Oropharynx</a> <span>/</span> <a href="/indications/DBCOND0029849">Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</a> <span>/</span> <a href="/indications/DBCOND0029850">Stage IVA Verrucous Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0029851">Stage IVA Verrucous Carcinoma of the Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0029852">Stage IVB Salivary Gland Cancer</a> <span>/</span> <a href="/indications/DBCOND0029853">Stage IVB Squamous Cell Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0029854">Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0029855">Stage IVB Squamous Cell Carcinoma of the Oropharynx</a> <span>/</span> <a href="/indications/DBCOND0029856">Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</a> <span>/</span> <a href="/indications/DBCOND0029857">Stage IVB Verrucous Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0029858">Stage IVB Verrucous Carcinoma of the Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0029859">Stage IVC Salivary Gland Cancer</a> <span>/</span> <a href="/indications/DBCOND0029837">Stage IVC Squamous Cell Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0029838">Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0029839">Stage IVC Squamous Cell Carcinoma of the Oropharynx</a> <span>/</span> <a href="/indications/DBCOND0029840">Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</a> <span>/</span> <a href="/indications/DBCOND0029841">Stage IVC Verrucous Carcinoma of the Larynx</a> <span>/</span> <a href="/indications/DBCOND0029842">Stage IVC Verrucous Carcinoma of the Oral Cavity</a> <span>/</span> <a href="/indications/DBCOND0029843">Tongue Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028809%2CDBCOND0029504%2CDBCOND0028811%2CDBCOND0028812%2CDBCOND0028813%2CDBCOND0028814%2CDBCOND0029505%2CDBCOND0029506%2CDBCOND0029507%2CDBCOND0029844%2CDBCOND0029520%2CDBCOND0028783%2CDBCOND0029845%2CDBCOND0029846%2CDBCOND0029847%2CDBCOND0029848%2CDBCOND0029849%2CDBCOND0029850%2CDBCOND0029851%2CDBCOND0029852%2CDBCOND0029853%2CDBCOND0029854%2CDBCOND0029855%2CDBCOND0029856%2CDBCOND0029857%2CDBCOND0029858%2CDBCOND0029859%2CDBCOND0029837%2CDBCOND0029838%2CDBCOND0029839%2CDBCOND0029840%2CDBCOND0029841%2CDBCOND0029842%2CDBCOND0029843&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0035874">Squamous Cell Carcinoma of the Head and Neck (SCCHN)</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0035874&amp;phase=2&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2</td><td>Not Yet Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0029875">Tumors Metastatic to Brain</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036%2CDBCOND0029875&amp;phase=2&amp;purpose=treatment&amp;status=not_yet_recruiting">1</a></td></tr><tr><td>2</td><td>Not Yet Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0020306">Melanoma</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0020306&amp;phase=2&amp;purpose=treatment&amp;status=not_yet_recruiting">1</a></td></tr><tr><td>2</td><td>Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0029933">Breast Diseases</a> <span>/</span> <a href="/indications/DBCOND0066658">Capecitabine</a> <span>/</span> <a href="/indications/DBCOND0066412">HER2 Positive Breast Cancers</a> <span>/</span> <a href="/indications/DBCOND0029216">HER2 Positive Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0029933%2CDBCOND0066658%2CDBCOND0066412%2CDBCOND0029216%2CDBCOND0030201&amp;phase=2&amp;purpose=treatment&amp;status=recruiting">1</a></td></tr><tr><td>2</td><td>Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0034881">Cancer of the Gallbladder</a> <span>/</span> <a href="/indications/DBCOND0029557">Cholangiocarcinoma of the Extrahepatic Bile Duct</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0034881%2CDBCOND0029557&amp;phase=2&amp;purpose=treatment&amp;status=recruiting">1</a></td></tr><tr><td>2</td><td>Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0066412">HER2 Positive Breast Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0066412&amp;phase=2&amp;purpose=treatment&amp;status=recruiting">1</a></td></tr><tr><td>2</td><td>Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0067750">Malignant Solid Neoplasms</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0067750&amp;phase=2&amp;purpose=treatment&amp;status=recruiting">1</a></td></tr><tr><td>2</td><td>Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030200&amp;phase=2&amp;purpose=treatment&amp;status=recruiting">2</a></td></tr><tr><td>2</td><td>Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201&amp;phase=2&amp;purpose=treatment&amp;status=recruiting">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0032762">Adenocarcinomas of the Gastroesophageal Junction</a> <span>/</span> <a href="/indications/DBCOND0045917">Malignant Neoplasm of Stomach</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0032762%2CDBCOND0045917&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0031019">Advanced Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0037730">HER2/Neu-positive Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0031019%2CDBCOND0028036%2CDBCOND0037730%2CDBCOND0030200&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=2&amp;purpose=treatment&amp;status=terminated">4</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0031006">Cancer of the Breast</a> <span>/</span> <a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036%2CDBCOND0031006%2CDBCOND0030201&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0003004">Carcinoma, Ductal, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0003004&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0055467">Endocrine Breast Diseases</a> <span>/</span> <a href="/indications/DBCOND0066909">Neoplasms Metastasis</a> <span>/</span> <a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0055467%2CDBCOND0066909%2CDBCOND0030201&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0115702">Gastroesophageal Cancer (GC)</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0115702&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0061990">HER2 Positive Esophagogastric Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0061990&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0046916">Lung Cancer Non-Small Cell Cancer (NSCLC)</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0046916&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0028546">Male Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028640">Recurrent Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028774">Stage IIIA Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028549">Stage IIIB Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0028641">Stage IIIC Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028546%2CDBCOND0028640%2CDBCOND0028774%2CDBCOND0028549%2CDBCOND0028641&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0034613">Malignancies</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0034613&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0020788">Cancer treatment</a> <span>/</span> <a href="/indications/DBCOND0034613">Malignancies</a> <span>/</span> <a href="/indications/DBCOND0036457">Ovarian</a> <span>/</span> <a href="/indications/DBCOND0047612">Relapses</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0020788%2CDBCOND0034613%2CDBCOND0036457%2CDBCOND0047612&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0087260">Malignant Neoplasm of Pancreas</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0087260&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0107071">Melanoma, Malignant</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0107071&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0054408">Metastatic Bladder Cancer</a> <span>/</span> <a href="/indications/DBCOND0028551">Recurrent Bladder Cancer</a> <span>/</span> <a href="/indications/DBCOND0028554">Stage III Bladder Cancer</a> <span>/</span> <a href="/indications/DBCOND0028556">Transitional Cell Carcinoma of the Bladder</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0054408%2CDBCOND0028551%2CDBCOND0028554%2CDBCOND0028556&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030200&amp;phase=2&amp;purpose=treatment&amp;status=terminated">6</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0032911">Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0032911&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201&amp;phase=2&amp;purpose=treatment&amp;status=terminated">3</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a> <span>/</span> <a href="/indications/DBCOND0037413">Relapsed Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201%2CDBCOND0037413&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0058909">Pancreatic Cancer Metastatic</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0058909&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0043488">Squamous Cell Carcinoma (SCC)</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0043488&amp;phase=2&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>2</td><td>Unknown Status</td><td>Treatment</td><td><a href="/indications/DBCOND0051389">ErbB2-Positive Stage I-III Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0051389&amp;phase=2&amp;purpose=treatment&amp;status=unknown_status">1</a></td></tr><tr><td>2</td><td>Unknown Status</td><td>Treatment</td><td><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030200&amp;phase=2&amp;purpose=treatment&amp;status=unknown_status">1</a></td></tr><tr><td>2</td><td>Withdrawn</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=2&amp;purpose=treatment&amp;status=withdrawn">2</a></td></tr><tr><td>2</td><td>Withdrawn</td><td>Treatment</td><td><a href="/indications/DBCOND0092003">Cancer, Bladder</a> <span>/</span> <a href="/indications/DBCOND0039244">Urothelial Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0092003%2CDBCOND0039244&amp;phase=2&amp;purpose=treatment&amp;status=withdrawn">1</a></td></tr><tr><td>2</td><td>Withdrawn</td><td>Treatment</td><td><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030200&amp;phase=2&amp;purpose=treatment&amp;status=withdrawn">1</a></td></tr><tr><td>2</td><td>Withdrawn</td><td>Treatment</td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201&amp;phase=2&amp;purpose=treatment&amp;status=withdrawn">3</a></td></tr><tr><td>2, 3</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0092003">Cancer, Bladder</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0092003&amp;phase=2%2C3&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>2, 3</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0066412">HER2 Positive Breast Cancers</a> <span>/</span> <a href="/indications/DBCOND0017410">Inflammatory carcinoma of breast stage IV</a> <span>/</span> <a href="/indications/DBCOND0017409">Inflammatory carcinoma of the breast</a> <span>/</span> <a href="/indications/DBCOND0047004">Invasive Ductal Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0064161">Malignant Neoplasm of Female Breast</a> <span>/</span> <a href="/indications/DBCOND0053761">Mucinous Breast Cancer Stage II</a> <span>/</span> <a href="/indications/DBCOND0053760">Tubular Breast Cancer Stage II</a> <span>/</span> <a href="/indications/DBCOND0053764">Tubular Breast Cancer Stage III</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0066412%2CDBCOND0017410%2CDBCOND0017409%2CDBCOND0047004%2CDBCOND0064161%2CDBCOND0053761%2CDBCOND0053760%2CDBCOND0053764&amp;phase=2%2C3&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>2, 3</td><td>Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0066412">HER2 Positive Breast Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0066412&amp;phase=2%2C3&amp;purpose=treatment&amp;status=recruiting">1</a></td></tr><tr><td>2, 3</td><td>Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0036640">Oesophagogastric Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0036640&amp;phase=2%2C3&amp;purpose=treatment&amp;status=recruiting">1</a></td></tr><tr><td>3</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=3&amp;purpose=treatment&amp;status=active_not_recruiting">3</a></td></tr><tr><td>3</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0067354">HER2 Positive Metastatic Breast Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0067354&amp;phase=3&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>3</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0124644">HER2-positive Advanced Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0124644&amp;phase=3&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>3</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0037365">Invasive Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0037365&amp;phase=3&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>3</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0030384">Male Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0092284">Stage IIA Breast Cancer AJCC v6 and v7</a> <span>/</span> <a href="/indications/DBCOND0092285">Stage IIB Breast Cancer AJCC v6 and v7</a> <span>/</span> <a href="/indications/DBCOND0092286">Stage IIIA Breast Cancer AJCC v7</a> <span>/</span> <a href="/indications/DBCOND0092287">Stage IIIB Breast Cancer AJCC v7</a> <span>/</span> <a href="/indications/DBCOND0092288">Stage IIIC Breast Cancer AJCC v7</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030384%2CDBCOND0092284%2CDBCOND0092285%2CDBCOND0092286%2CDBCOND0092287%2CDBCOND0092288&amp;phase=3&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>3</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030200&amp;phase=3&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>3</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201&amp;phase=3&amp;purpose=treatment&amp;status=active_not_recruiting">4</a></td></tr><tr><td>3</td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0037762">Neoplasms, Gastrointestinal Tract</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0037762&amp;phase=3&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td>3</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=3&amp;purpose=treatment&amp;status=completed">3</a></td></tr><tr><td>3</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0031389">Estrogen Receptor Positive</a> <span>/</span> <a href="/indications/DBCOND0029216">HER2 Positive Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0034239">HER2/Neu Negative</a> <span>/</span> <a href="/indications/DBCOND0031390">Progesterone Receptor Positive</a> <span>/</span> <a href="/indications/DBCOND0030216">Recurrent Breast Carcinoma</a> <span>/</span> <a href="/indications/DBCOND0028549">Stage IIIB Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0092287">Stage IIIB Breast Cancer AJCC v7</a> <span>/</span> <a href="/indications/DBCOND0028641">Stage IIIC Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0092288">Stage IIIC Breast Cancer AJCC v7</a> <span>/</span> <a href="/indications/DBCOND0028550">Stage IV Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0092437">Stage IV Breast Cancer AJCC v6 and v7</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0031389%2CDBCOND0029216%2CDBCOND0034239%2CDBCOND0031390%2CDBCOND0030216%2CDBCOND0028549%2CDBCOND0092287%2CDBCOND0028641%2CDBCOND0092288%2CDBCOND0028550%2CDBCOND0092437&amp;phase=3&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>3</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0062591">HER2+ Metastatic Breast Cancer (MBC)</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0062591&amp;phase=3&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>3</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201&amp;phase=3&amp;purpose=treatment&amp;status=completed">6</a></td></tr><tr><td>3</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0037762">Neoplasms, Gastrointestinal Tract</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0037762&amp;phase=3&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>3</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0036314">Neoplasms, Head and Neck</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0036314&amp;phase=3&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>3</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0029875">Tumors Metastatic to Brain</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0029875&amp;phase=3&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td>3</td><td>Recruiting</td><td>Health Services Research</td><td><a href="/indications/DBCOND0056871">Soft Tissue Sarcoma (STS)</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0056871&amp;phase=3&amp;purpose=health_services_research&amp;status=recruiting">1</a></td></tr><tr><td>3</td><td>Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=3&amp;purpose=treatment&amp;status=recruiting">1</a></td></tr><tr><td>3</td><td>Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0055533">Her2-negative Metastatic Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0057766">HER2-positive Circulating Tumor Cells</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0055533%2CDBCOND0057766&amp;phase=3&amp;purpose=treatment&amp;status=recruiting">1</a></td></tr><tr><td>3</td><td>Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0030200">Metastatic Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030200&amp;phase=3&amp;purpose=treatment&amp;status=recruiting">2</a></td></tr><tr><td>3</td><td>Terminated</td><td>Treatment</td><td><a href="/indications/DBCOND0034613">Malignancies</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0034613&amp;phase=3&amp;purpose=treatment&amp;status=terminated">1</a></td></tr><tr><td>3</td><td>Unknown Status</td><td>Treatment</td><td><a href="/indications/DBCOND0028036">Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036&amp;phase=3&amp;purpose=treatment&amp;status=unknown_status">1</a></td></tr><tr><td>4</td><td>Approved for Marketing</td><td><span class='not-available'>Not Available</span></td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201&amp;phase=4&amp;status=approved_for_marketing">1</a></td></tr><tr><td>4</td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0034613">Malignancies</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0034613&amp;phase=4&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td><span class='not-available'>Not Available</span></td><td>Active Not Recruiting</td><td>Diagnostic</td><td><a href="/indications/DBCOND0030110">Advanced Solid Tumors</a> <span>/</span> <a href="/indications/DBCOND0034613">Malignancies</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030110%2CDBCOND0034613&amp;purpose=diagnostic&amp;status=active_not_recruiting">1</a></td></tr><tr><td><span class='not-available'>Not Available</span></td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0030110">Advanced Solid Tumors</a> <span>/</span> <a href="/indications/DBCOND0048964">Inoperable</a> <span>/</span> <a href="/indications/DBCOND0017341">Metastasis</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030110%2CDBCOND0048964%2CDBCOND0017341&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td><span class='not-available'>Not Available</span></td><td>Active Not Recruiting</td><td>Treatment</td><td><a href="/indications/DBCOND0049168">Metastatic Triple Negative Breast Cancer</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0049168&amp;purpose=treatment&amp;status=active_not_recruiting">1</a></td></tr><tr><td><span class='not-available'>Not Available</span></td><td>Completed</td><td><span class='not-available'>Not Available</span></td><td><a href="/indications/DBCOND0028036">Breast Cancer</a> <span>/</span> <a href="/indications/DBCOND0060442">Metastatic Cancers</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0028036%2CDBCOND0060442&amp;status=completed">1</a></td></tr><tr><td><span class='not-available'>Not Available</span></td><td>Completed</td><td><span class='not-available'>Not Available</span></td><td><a href="/indications/DBCOND0034613">Malignancies</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0034613&amp;status=completed">3</a></td></tr><tr><td><span class='not-available'>Not Available</span></td><td>Completed</td><td><span class='not-available'>Not Available</span></td><td><a href="/indications/DBCOND0030201">Neoplasms, Breast</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0030201&amp;status=completed">1</a></td></tr><tr><td><span class='not-available'>Not Available</span></td><td>Completed</td><td>Treatment</td><td><a href="/indications/DBCOND0042203">Ductal Breast Carcinoma In Situ</a> <span>/</span> <a href="/indications/DBCOND0066412">HER2 Positive Breast Cancers</a> <span>/</span> <a href="/indications/DBCOND0037939">HER2/Neu Positive</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0042203%2CDBCOND0066412%2CDBCOND0037939&amp;purpose=treatment&amp;status=completed">1</a></td></tr><tr><td><span class='not-available'>Not Available</span></td><td>Terminated</td><td>Basic Science</td><td><a href="/indications/DBCOND0037614">Ductal Carcinoma In Situ</a></td><td><a href="/drugs/DB01259/clinical_trials?conditions=DBCOND0037614&amp;purpose=basic_science&amp;status=terminated">1</a></td></tr></tbody></table></dd></dl><h2 id="pharmacoeconomics" class="section-header">Pharmacoeconomics</h2><dl><dt class="col-md-2 col-sm-4">Manufacturers</dt><dd class="col-md-10 col-sm-8"><div class="manufacturer-columns"><span class='not-available'>Not Available</span></div></dd><dt class="col-md-2 col-sm-4">Packagers</dt><dd class="col-md-10 col-sm-8"><div class="packager-columns"><ul class="list-unstyled table-list"><li>GlaxoSmithKline Inc.</li></ul></div></dd><dt class="col-md-2 col-sm-4">Dosage forms</dt><dd class="col-md-10 col-sm-8"><table class="table table-sm datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>250 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>250 mg/1</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>250 mg</td></tr></tbody></table></dd><dt class="col-md-2 col-sm-4">Prices</dt><dd class="col-md-10 col-sm-8"><table class="table table-sm datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Tykerb 250 mg tablet</td><td>28.4USD </td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix price-alert"><span class="glyphicon glyphicon-info-sign"> </span> DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only. </div></dd><dt class="col-md-2 col-sm-4">Patents</dt><dd class="col-md-10 col-sm-8 has-locked-content"><table class="table table-sm datatable dt-responsive" id="patents" style="width: 100%"><thead><tr><th>Patent Number</th><th>Pediatric Extension</th><th>Approved</th><th>Expires (estimated)</th><th></th></tr><tr class="unlock-row"><th class="no-sort" colspan="5"><div class="locked-link" data-field="patents" data-target="#locked-modal" data-toggle="modal"><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div> Unlock Additional Data</div></th></tr></thead><tbody><tr><td><a target="_blank" rel="noopener" href="https://patents.google.com/patent/CA2413134">CA2413134</a></td><td><span class="badge badge-secondary badge-pill ">No</span></td><td>2010-05-11</td><td>2021-06-28</td><td class="country"><span class="country"><span hidden="hidden">Canada</span><img src="/assets/countries/canada-64ffe8c476c257597eca3ded684da90a2b1a500bd6389ebd2ca5e213b1cc7574.svg" alt="Canada" /></span></td></tr><tr><td><a target="_blank" rel="noopener" href="https://patents.google.com/patent/CA2317589">CA2317589</a></td><td><span class="badge badge-secondary badge-pill ">No</span></td><td>2007-08-08</td><td>2019-01-08</td><td class="country"><span class="country"><span hidden="hidden">Canada</span><img src="/assets/countries/canada-64ffe8c476c257597eca3ded684da90a2b1a500bd6389ebd2ca5e213b1cc7574.svg" alt="Canada" /></span></td></tr><tr><td><a target="_blank" rel="noopener" href="https://patents.google.com/patent/US6391874">US6391874</a></td><td><span class="badge badge-secondary badge-pill ">No</span></td><td>2002-05-21</td><td>2017-07-11</td><td class="country"><span class="country"><span hidden="hidden">US</span><img src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg" alt="Us" /></span></td></tr><tr><td><a target="_blank" rel="noopener" href="https://patents.google.com/patent/US6713485">US6713485</a></td><td><span class="badge badge-secondary badge-pill ">No</span></td><td>2004-03-30</td><td>2020-09-29</td><td class="country"><span class="country"><span hidden="hidden">US</span><img src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg" alt="Us" /></span></td></tr><tr><td><a target="_blank" rel="noopener" href="https://patents.google.com/patent/US6727256">US6727256</a></td><td><span class="badge badge-secondary badge-pill ">No</span></td><td>2004-04-27</td><td>2019-01-08</td><td class="country"><span class="country"><span hidden="hidden">US</span><img src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg" alt="Us" /></span></td></tr><tr><td><a target="_blank" rel="noopener" href="https://patents.google.com/patent/US6828320">US6828320</a></td><td><span class="badge badge-secondary badge-pill ">No</span></td><td>2004-12-07</td><td>2017-07-11</td><td class="country"><span class="country"><span hidden="hidden">US</span><img src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg" alt="Us" /></span></td></tr><tr><td><a target="_blank" rel="noopener" href="https://patents.google.com/patent/US8821927">US8821927</a></td><td><span class="badge badge-secondary badge-pill ">No</span></td><td>2014-09-02</td><td>2029-09-18</td><td class="country"><span class="country"><span hidden="hidden">US</span><img src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg" alt="Us" /></span></td></tr><tr><td><a target="_blank" rel="noopener" href="https://patents.google.com/patent/US8513262">US8513262</a></td><td><span class="badge badge-secondary badge-pill ">No</span></td><td>2013-08-20</td><td>2019-01-08</td><td class="country"><span class="country"><span hidden="hidden">US</span><img src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg" alt="Us" /></span></td></tr><tr><td><a target="_blank" rel="noopener" href="https://patents.google.com/patent/US7157466">US7157466</a></td><td><span class="badge badge-secondary badge-pill ">No</span></td><td>2007-01-02</td><td>2021-11-19</td><td class="country"><span class="country"><span hidden="hidden">US</span><img src="/assets/countries/us-827348b033d3b349931e036455f341029a75d10b2533057ebfbfdb0ca0e45c47.svg" alt="Us" /></span></td></tr></tbody></table><div class="locked-fields-holder" data-for="#patents"><div class="locked-fields closed" data-collapsed="collapsed"><div class="locked-tab"><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div><span class="tab-label">Additional Data Available</span><div class="drugbank-icon icon-arrow-left"><svg class="icon" role="img" title="arrow-left"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#arrow-left"> </use></svg></div><div class="drugbank-icon icon-arrow-right"><svg class="icon" role="img" title="arrow-right"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#arrow-right"> </use></svg></div></div><ul class="locked-accordion"><div class="flex-content"><li class="closed"><div class="flex-content"><div class="locked-header">Filed On <div class="drugbank-icon icon-plus"><svg class="icon" role="img" title="plus"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#plus"> </use></svg></div></div><div class="locked-content"><div class="locked-info"><div class="close-tab drugbank-icon icon-exit"><svg class="icon" role="img" title="exit"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#exit"> </use></svg></div><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div><div class="locked-panel-header">Filed On</div><p>The date on which a patent was filed with the relevant government.</p><a class="btn btn-sm btn-pink track-link" target="_blank" data-link-id="locked/patents-filed-on" href="https://drugbankplus.com/scientific">Learn more</a></div></div></div></li></div></ul></div></div></dd></dl><h2 id="properties" class="section-header">Properties</h2><dl><dt class="col-md-2 col-sm-4">State</dt><dd class="col-md-10 col-sm-8">Solid</dd><dt class="col-md-2 col-sm-4">Experimental Properties</dt><dd class="col-md-10 col-sm-8"><table class="table table-sm table-bordered" id="experimental-properties"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>logP</td><td>5.4</td><td><span class='not-available'>Not Available</span></td></tr></tbody></table></dd><dt class="col-md-2 col-sm-4">Predicted Properties</dt><dd class="col-md-10 col-sm-8"><table class="table table-sm responsive-table" id="drug-moldb-properties"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>Water Solubility</td><td>0.0223 mg/mL</td><td><a target="_blank" rel="noopener" href="http://www.vcclab.org/lab/alogps/">ALOGPS</a></td></tr><tr><td>logP</td><td>5.18</td><td><a target="_blank" rel="noopener" href="http://www.vcclab.org/lab/alogps/">ALOGPS</a></td></tr><tr><td>logP</td><td>4.64</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4.4</td><td><a target="_blank" rel="noopener" href="http://www.vcclab.org/lab/alogps/">ALOGPS</a></td></tr><tr><td>pKa (Strongest Acidic)</td><td>15.99</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (Strongest Basic)</td><td>7.2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>Physiological Charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>Hydrogen Acceptor Count</td><td>7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>Hydrogen Donor Count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>Polar Surface Area</td><td>106.35 Å<sup>2</sup></td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>Rotatable Bond Count</td><td>11</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>Refractivity</td><td>152.42 m<sup>3</sup>·mol<sup>-1</sup></td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>Polarizability</td><td>61.19 Å<sup>3</sup></td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Number of Rings</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>Bioavailability</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Rule of Five</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose Filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's Rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like Rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></dd><dt class="col-md-2 col-sm-4">Predicted ADMET features</dt><dd class="col-md-10 col-sm-8"><table class="table table-sm responsive-table" id="drug-predicted-admet"><thead><tr><th>Property</th><th>Value</th><th>Probability</th></tr></thead><tbody><tr><td>Human Intestinal Absorption</td><td>+</td><td>1.0</td></tr><tr><td>Blood Brain Barrier</td><td>+</td><td>0.6201</td></tr><tr><td>Caco-2 permeable</td><td>-</td><td>0.5858</td></tr><tr><td>P-glycoprotein substrate</td><td>Substrate</td><td>0.7403</td></tr><tr><td>P-glycoprotein inhibitor I</td><td>Inhibitor</td><td>0.5414</td></tr><tr><td>P-glycoprotein inhibitor II</td><td>Non-inhibitor</td><td>0.7799</td></tr><tr><td>Renal organic cation transporter</td><td>Non-inhibitor</td><td>0.7442</td></tr><tr><td>CYP450 2C9 substrate</td><td>Non-substrate</td><td>0.6688</td></tr><tr><td>CYP450 2D6 substrate</td><td>Non-substrate</td><td>0.7644</td></tr><tr><td>CYP450 3A4 substrate</td><td>Substrate</td><td>0.6619</td></tr><tr><td>CYP450 1A2 substrate</td><td>Inhibitor</td><td>0.5386</td></tr><tr><td>CYP450 2C9 inhibitor</td><td>Non-inhibitor</td><td>0.5544</td></tr><tr><td>CYP450 2D6 inhibitor</td><td>Non-inhibitor</td><td>0.7861</td></tr><tr><td>CYP450 2C19 inhibitor</td><td>Inhibitor</td><td>0.5274</td></tr><tr><td>CYP450 3A4 inhibitor</td><td>Inhibitor</td><td>0.8065</td></tr><tr><td>CYP450 inhibitory promiscuity</td><td>High CYP Inhibitory Promiscuity</td><td>0.9104</td></tr><tr><td>Ames test</td><td>Non AMES toxic</td><td>0.543</td></tr><tr><td>Carcinogenicity</td><td>Non-carcinogens</td><td>0.6788</td></tr><tr><td>Biodegradation</td><td>Not ready biodegradable</td><td>1.0</td></tr><tr><td>Rat acute toxicity</td><td>2.5867 LD50, mol/kg </td><td><span class='not-available'>Not applicable</span></td></tr><tr><td>hERG inhibition (predictor I)</td><td>Strong inhibitor</td><td>0.537</td></tr><tr><td>hERG inhibition (predictor II)</td><td>Inhibitor</td><td>0.8417</td></tr></tbody></table><div class="alert alert-warning clearfix admetsar-alert"><span class="glyphicon glyphicon-info-sign"> </span> ADMET data is predicted using <a href="http://lmmd.ecust.edu.cn:8000">admetSAR</a>, a free tool for evaluating chemical ADMET properties. (<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/23092397">23092397</a>) </div></dd></dl><h2 id="spectra" class="section-header">Spectra</h2><dl><dt class="col-md-2 col-sm-4">Mass Spec (NIST)</dt><dd class="col-md-10 col-sm-8"><span class='not-available'>Not Available</span></dd><dt class="col-md-2 col-sm-4">Spectra</dt><dd class="col-md-10 col-sm-8"><table class="table table-sm responsive-table" id="drug-spectra-table"><thead><tr><th>Spectrum</th><th>Spectrum Type</th><th><a target="_blank" rel="noopener" href="http://splash.fiehnlab.ucdavis.edu/">Splash Key</a></th></tr></thead><tbody data-no-turbolink=""><tr><td><a href="/spectra/c_ms/25723">Predicted GC-MS Spectrum - GC-MS</a></td><td>Predicted GC-MS</td><td><span class='not-available'>Not Available</span></td></tr><tr><td><a href="/spectra/ms_ms/107343">Predicted MS/MS Spectrum - 10V, Positive (Annotated)</a></td><td>Predicted LC-MS/MS</td><td><span class='not-available'>Not Available</span></td></tr><tr><td><a href="/spectra/ms_ms/107344">Predicted MS/MS Spectrum - 20V, Positive (Annotated)</a></td><td>Predicted LC-MS/MS</td><td><span class='not-available'>Not Available</span></td></tr><tr><td><a href="/spectra/ms_ms/107345">Predicted MS/MS Spectrum - 40V, Positive (Annotated)</a></td><td>Predicted LC-MS/MS</td><td><span class='not-available'>Not Available</span></td></tr><tr><td><a href="/spectra/ms_ms/174303">Predicted MS/MS Spectrum - 10V, Negative (Annotated)</a></td><td>Predicted LC-MS/MS</td><td><span class='not-available'>Not Available</span></td></tr><tr><td><a href="/spectra/ms_ms/174304">Predicted MS/MS Spectrum - 20V, Negative (Annotated)</a></td><td>Predicted LC-MS/MS</td><td><span class='not-available'>Not Available</span></td></tr><tr><td><a href="/spectra/ms_ms/174305">Predicted MS/MS Spectrum - 40V, Negative (Annotated)</a></td><td>Predicted LC-MS/MS</td><td><span class='not-available'>Not Available</span></td></tr><tr><td><a href="/spectra/ms_ms/374312">LC-MS/MS Spectrum - LC-ESI-qTof , Positive</a></td><td>LC-MS/MS</td><td><span class='not-available'>Not Available</span></td></tr><tr><td><a href="/spectra/ms_ms/450826">MS/MS Spectrum - , positive</a></td><td>LC-MS/MS</td><td><a target="_blank" rel="noopener" href="http://mona.fiehnlab.ucdavis.edu/#/spectra/splash/splash10-00lr-0009070000-0d55ba750eaa2fb12020">splash10-00lr-0009070000-0d55ba750eaa2fb12020</a></td></tr><tr><td><a href="/spectra/ms_ms/450827">MS/MS Spectrum - , positive</a></td><td>LC-MS/MS</td><td><a target="_blank" rel="noopener" href="http://mona.fiehnlab.ucdavis.edu/#/spectra/splash/splash10-0ab9-0649800000-87742edfe3489dab4ac8">splash10-0ab9-0649800000-87742edfe3489dab4ac8</a></td></tr></tbody></table></dd></dl><h2 id="taxonomy" class="section-header">Taxonomy</h2><dl><dt class="col-md-2 col-sm-4">Description</dt><dd class="col-md-10 col-sm-8">This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.</dd><dt class="col-md-2 col-sm-4">Kingdom</dt><dd class="col-md-10 col-sm-8"><a title="Compounds that contain at least one carbon atom, excluding isocyanide/cyanide and their non-hydrocarbyl derivatives, thiophosgene, carbon diselenide, carbon monosulfide, carbon disulfide, carbon subsulfide, carbon monoxide, carbon dioxide, Carbon suboxide, and dicarbon monoxide." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0000000">Organic compounds</a></dd><dt class="col-md-2 col-sm-4">Super Class</dt><dd class="col-md-10 col-sm-8"><a title="Compounds containing a ring with least one carbon atom and one non-carbon atom." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0000002">Organoheterocyclic compounds</a></dd><dt class="col-md-2 col-sm-4">Class</dt><dd class="col-md-10 col-sm-8"><a title="Aromatic heterocyclic chemical compounds containing a naphthalene derivative, where two carbon atoms are replaced by nitrogen atoms. They are subdivided in benzodiazines and naphthyridines." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0004788">Diazanaphthalenes</a></dd><dt class="col-md-2 col-sm-4">Sub Class</dt><dd class="col-md-10 col-sm-8"><a title="Aromatic heterocyclic compounds containing a benzene ring fused to a diazine ring. The diazine ring is an analogue of benzene, where two carbon atoms are replaced by nitrogen atoms." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0004789">Benzodiazines</a></dd><dt class="col-md-2 col-sm-4">Direct Parent</dt><dd class="col-md-10 col-sm-8"><a title="Heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0002314">Quinazolinamines</a></dd><dt class="col-md-2 col-sm-4">Alternative Parents</dt><dd class="col-md-10 col-sm-8"><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a title="Aromatic compounds contaning a phenoxy group." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0004742">Phenoxy compounds</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Aromatic compounds containing an ether group substituted with a benzene ring." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0002341">Phenol ethers</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Organic compounds containing an aminobenzene moiety." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0000284">Aniline and substituted anilines</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Organic compounds containing the alkyl aryl ether functional group with the generic formula R-O-R&#39; , where R is an alkyl group and R&#39; is an aryl group." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0000128">Alkyl aryl ethers</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Organic compounds containing an amino group attached to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0001262">Aminopyrimidines and derivatives</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0003899">Aralkylamines</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Compounds containing one or more chlorine atoms attached to a benzene moiety." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0001099">Chlorobenzenes</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Compounds containing one or more fluorine atoms attached to a benzene ring." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0001100">Fluorobenzenes</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Organic compounds containing the acyl chloride functional group." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0001030">Aryl chlorides</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Organic compounds containing the acyl fluoride functional group." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0001031">Aryl fluorides</a></span></span></span><span class="hidden-taxonomy" style="display: none"><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a title="Cyclic organooxygen compounds containing the structure RC(=N)N where the central carbon atom and one of the linked nitrogen atoms are part of the same ring( R here is an organyl group). They can also be viewed as analogs of lactams where the oxygen atom is replaced by a nitrogen atom." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0003886">Imidolactams</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Compounds containing a sulfonyl group( which as the general structure RS(=O)2R&#39; (R,R&#39; =alkyl, aryl)) attached to two carbon atoms." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0000505">Sulfones</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Compounds containing an aromatic ring where a carbon atom is linked to an hetero atom." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0004144">Heteroaromatic compounds</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Compounds containing a furan ring, which is a five-member aromatic ring with one oxygen atom, four carbon atoms." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0000076">Furans</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Organic compounds containing an heterocycle with at least one nitrogen atom and one carbon atom linked to each other." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0004139">Azacyclic compounds</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Organic compounds containing a dialkylamine group, characterized by two alkyl groups bonded to the amino nitrogen." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0002228">Dialkylamines</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Organic compounds containing an heterocycle with at least one oxygen atom linked to a ring carbon." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0004140">Oxacyclic compounds</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Derivatives of hydrocarbons obtained by substituting one or more carbon atoms by an heteroatom. They contain at least one carbon atom and heteroatom." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0004150">Hydrocarbon derivatives</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Organic compounds containing an oxide group." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0003940">Organic oxides</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Compounds containing a chemical bond between a carbon atom and a chlorine atom." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0001516">Organochlorides</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Compounds containing a chemical bond between a carbon atom and a fluorine atom." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0001517">Organofluorides</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a title="Compounds containing a bond between carbon a pnictogen atom. Pnictogens are p-block element atoms that are in the group 15 of the periodic table." class="classyfire-taxnode" target="_blank" rel="noopener" href="http://classyfire.wishartlab.com/tax_nodes/C0004557">Organopnictogen compounds</a></span></span></span></span><a class="taxonomy-toggler" href="javascript:void();"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#expand"> </use></svg></div> show 12 more</a></dd><dt class="col-md-2 col-sm-4">Substituents</dt><dd class="col-md-10 col-sm-8"><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item">Quinazolinamine</span><span class='list-separator'> / </span><span class="separated-list-item">Phenol ether</span><span class='list-separator'> / </span><span class="separated-list-item">Phenoxy compound</span><span class='list-separator'> / </span><span class="separated-list-item">Aniline or substituted anilines</span><span class='list-separator'> / </span><span class="separated-list-item">Halobenzene</span><span class='list-separator'> / </span><span class="separated-list-item">Alkyl aryl ether</span><span class='list-separator'> / </span><span class="separated-list-item">Aminopyrimidine</span><span class='list-separator'> / </span><span class="separated-list-item">Fluorobenzene</span><span class='list-separator'> / </span><span class="separated-list-item">Aralkylamine</span><span class='list-separator'> / </span><span class="separated-list-item">Chlorobenzene</span></span></span><span class="hidden-taxonomy" style="display: none"><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item">Imidolactam</span><span class='list-separator'> / </span><span class="separated-list-item">Benzenoid</span><span class='list-separator'> / </span><span class="separated-list-item">Aryl chloride</span><span class='list-separator'> / </span><span class="separated-list-item">Pyrimidine</span><span class='list-separator'> / </span><span class="separated-list-item">Monocyclic benzene moiety</span><span class='list-separator'> / </span><span class="separated-list-item">Aryl halide</span><span class='list-separator'> / </span><span class="separated-list-item">Aryl fluoride</span><span class='list-separator'> / </span><span class="separated-list-item">Furan</span><span class='list-separator'> / </span><span class="separated-list-item">Sulfonyl</span><span class='list-separator'> / </span><span class="separated-list-item">Sulfone</span><span class='list-separator'> / </span><span class="separated-list-item">Heteroaromatic compound</span><span class='list-separator'> / </span><span class="separated-list-item">Oxacycle</span><span class='list-separator'> / </span><span class="separated-list-item">Azacycle</span><span class='list-separator'> / </span><span class="separated-list-item">Secondary aliphatic amine</span><span class='list-separator'> / </span><span class="separated-list-item">Ether</span><span class='list-separator'> / </span><span class="separated-list-item">Secondary amine</span><span class='list-separator'> / </span><span class="separated-list-item">Organosulfur compound</span><span class='list-separator'> / </span><span class="separated-list-item">Organopnictogen compound</span><span class='list-separator'> / </span><span class="separated-list-item">Organic oxygen compound</span><span class='list-separator'> / </span><span class="separated-list-item">Amine</span><span class='list-separator'> / </span><span class="separated-list-item">Organic nitrogen compound</span><span class='list-separator'> / </span><span class="separated-list-item">Hydrocarbon derivative</span><span class='list-separator'> / </span><span class="separated-list-item">Organic oxide</span><span class='list-separator'> / </span><span class="separated-list-item">Organooxygen compound</span><span class='list-separator'> / </span><span class="separated-list-item">Organohalogen compound</span><span class='list-separator'> / </span><span class="separated-list-item">Organochloride</span><span class='list-separator'> / </span><span class="separated-list-item">Organofluoride</span><span class='list-separator'> / </span><span class="separated-list-item">Organonitrogen compound</span><span class='list-separator'> / </span><span class="separated-list-item">Aromatic heteropolycyclic compound</span></span></span></span><a class="taxonomy-toggler" href="javascript:void();"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#expand"> </use></svg></div> show 29 more</a></dd><dt class="col-md-2 col-sm-4">Molecular Framework</dt><dd class="col-md-10 col-sm-8">Aromatic heteropolycyclic compounds</dd><dt class="col-md-2 col-sm-4">External Descriptors</dt><dd class="col-md-10 col-sm-8"><span class="inline-separated-list-container"><span class="simple-separated-list-item">organofluorine compound, organochlorine compound, furans, quinazolines (<a target="_blank" rel="noopener" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:49603">CHEBI:49603</a>) </span></span></dd></dl><div class="bond-list-container targets"><h3 id="targets">Targets</h3><div class="bond-list"><div class="bond card" id="BE0000767"><div aria-hidden="true" aria-labelledby="binding properties" class="modal fade" id="BE0000767-binding-properties" role="dialog" tabindex="-1"><div class="modal-dialog modal-lg"><div class="modal-content"><div class="modal-header"><h5 class="modal-title">Binding Properties</h5><button aria-hidden="true" class="close" data-dismiss="modal" type="button">&times;</button></div><div class="modal-body"><div class="table-responsive"><table class="table table-sm"><thead><tr><th>Property</th><th>Measurement</th><th>pH</th><th>Temperature (°C)</th><th>References</th></tr></thead><tbody><tr><td>IC 50 (nM)</td><td>10</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/16483772">16483772</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20166671">20166671</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22101132">22101132</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>10</td><td>7.5</td><td>23</td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/14684309">14684309</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>11.2</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20143778">20143778</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>12</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/16777410">16777410</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>17</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/19170633">19170633</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>2.9</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/21080629">21080629</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>433</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20817523">20817523</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>52</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/19888761">19888761</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20346655">20346655</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>52.2</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22372864">22372864</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>8</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22227214">22227214</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>8.9</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22169601">22169601</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>9</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22182581">22182581</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22595177">22595177</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>&gt;10000</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22037378">22037378</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>0.92</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18183025">18183025</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22037378">22037378</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>1.2</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18183025">18183025</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22037378">22037378</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>2.1</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18183025">18183025</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22037378">22037378</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>2.2</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18183025">18183025</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22037378">22037378</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>2.4</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18183025">18183025</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22037378">22037378</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>2.8</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18183025">18183025</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22037378">22037378</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>3.5</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18183025">18183025</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22037378">22037378</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>3.9</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18183025">18183025</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22037378">22037378</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>4.2</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18183025">18183025</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22037378">22037378</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>5.5</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/15711537">15711537</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>8.6</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18183025">18183025</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22037378">22037378</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>860</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22037378">22037378</a></span></span></span></td></tr></tbody></table></div></div></div></div></div><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P00533"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#expand"> </use></svg></div> Details</a><button class="btn btn-sm btn-drugbank-secondary" data-target="#BE0000767-binding-properties" data-toggle="modal" type="button"><div class="drugbank-icon icon-details"><svg class="icon" role="img" title="details"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#details"> </use></svg></div> <span class='full-binding-label'>Binding Properties</a></button><strong>1. <a href="/polypeptides/P00533">Epidermal growth factor receptor</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-yes">Yes</div></dd><dt class="col-md-5 col-sm-6">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Antagonist</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6">General Function</dt><dd class="col-md-7 col-sm-6">Ubiquitin protein ligase binding</dd><dt class="col-md-5 col-sm-6">Specific Function</dt><dd class="col-md-7 col-sm-6">Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TG...</dd><dt class="col-md-5 col-sm-6">Gene Name</dt><dd class="col-md-7 col-sm-6">EGFR</dd><dt class="col-md-5 col-sm-6">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P00533">P00533</a></dd><dt class="col-md-5 col-sm-6">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Epidermal growth factor receptor</dd><dt class="col-md-5 col-sm-6">Molecular Weight</dt><dd class="col-md-7 col-sm-6">134276.185 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A11416">Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002 Sep 12;21(41):6255-63. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/12214266">PubMed:12214266</a>] </li><li id="reference-A11417">Grana TM, Sartor CI, Cox AD: Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance. Cancer Res. 2003 Nov 15;63(22):7807-14. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/14633707">PubMed:14633707</a>] </li><li id="reference-A11418">Xia W, Liu LH, Ho P, Spector NL: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene. 2004 Jan 22;23(3):646-53. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/14737100">PubMed:14737100</a>] </li><li id="reference-A11419">Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI: Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):344-52. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/14751502">PubMed:14751502</a>] </li><li id="reference-A11420">Langer CJ: Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):991-1002. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/14967461">PubMed:14967461</a>] </li><li id="reference-A2249">Burris HA 3rd: Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9 Suppl 3:10-5. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/15163842">PubMed:15163842</a>] </li><li id="reference-A11421">Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L: A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004 Sep 15;64(18):6652-9. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/15374980">PubMed:15374980</a>] </li><li id="reference-A11422">Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B, Menendez JA: Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. J Cell Physiol. 2011 Jan;226(1):52-7. doi: 10.1002/jcp.22333. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20658522">PubMed:20658522</a>] </li><li id="reference-A2252">Johnston SR, Leary A: Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc). 2006 Jul;42(7):441-53. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/16894399">PubMed:16894399</a>] </li><li id="reference-A2253">Tevaarwerk AJ, Kolesar JM: Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009;31 Pt 2:2332-48. doi: 10.1016/j.clinthera.2009.11.029. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20110044">PubMed:20110044</a>] </li><li id="reference-A2254">Medina PJ, Goodin S: Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18803986">PubMed:18803986</a>] </li><li id="reference-A9">Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/11752352">PubMed:11752352</a>] </li></ol></div></div></div><div class="bond card" id="BE0000511"><div aria-hidden="true" aria-labelledby="binding properties" class="modal fade" id="BE0000511-binding-properties" role="dialog" tabindex="-1"><div class="modal-dialog modal-lg"><div class="modal-content"><div class="modal-header"><h5 class="modal-title">Binding Properties</h5><button aria-hidden="true" class="close" data-dismiss="modal" type="button">&times;</button></div><div class="modal-body"><div class="table-responsive"><table class="table table-sm"><thead><tr><th>Property</th><th>Measurement</th><th>pH</th><th>Temperature (°C)</th><th>References</th></tr></thead><tbody><tr><td>IC 50 (nM)</td><td>10</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/16777410">16777410</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20166671">20166671</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>10.2</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20143778">20143778</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>10.3</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22182581">22182581</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>100</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20346655">20346655</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>140</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20817523">20817523</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>36</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/19888761">19888761</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>36.3</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22372864">22372864</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>4.5</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/21080629">21080629</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>60</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22169601">22169601</a></span></span></span></td></tr><tr><td>IC 50 (nM)</td><td>9</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/16483772">16483772</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18500794">18500794</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22101132">22101132</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>11</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/15711537">15711537</a></span></span></span></td></tr><tr><td>Kd (nM)</td><td>7</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18183025">18183025</a></span><span class='list-separator'> / </span><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22037378">22037378</a></span></span></span></td></tr></tbody></table></div></div></div></div></div><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P04626"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#expand"> </use></svg></div> Details</a><button class="btn btn-sm btn-drugbank-secondary" data-target="#BE0000511-binding-properties" data-toggle="modal" type="button"><div class="drugbank-icon icon-details"><svg class="icon" role="img" title="details"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#details"> </use></svg></div> <span class='full-binding-label'>Binding Properties</a></button><strong>2. <a href="/polypeptides/P04626">Receptor tyrosine-protein kinase erbB-2</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-yes">Yes</div></dd><dt class="col-md-5 col-sm-6">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Antagonist</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6">General Function</dt><dd class="col-md-7 col-sm-6">Transmembrane signaling receptor activity</dd><dt class="col-md-5 col-sm-6">Specific Function</dt><dd class="col-md-7 col-sm-6">Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, alt...</dd><dt class="col-md-5 col-sm-6">Gene Name</dt><dd class="col-md-7 col-sm-6">ERBB2</dd><dt class="col-md-5 col-sm-6">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P04626">P04626</a></dd><dt class="col-md-5 col-sm-6">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Receptor tyrosine-protein kinase erbB-2</dd><dt class="col-md-5 col-sm-6">Molecular Weight</dt><dd class="col-md-7 col-sm-6">137909.27 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A11418">Xia W, Liu LH, Ho P, Spector NL: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene. 2004 Jan 22;23(3):646-53. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/14737100">PubMed:14737100</a>] </li><li id="reference-A11419">Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI: Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):344-52. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/14751502">PubMed:14751502</a>] </li><li id="reference-A11420">Langer CJ: Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):991-1002. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/14967461">PubMed:14967461</a>] </li><li id="reference-A2249">Burris HA 3rd: Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9 Suppl 3:10-5. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/15163842">PubMed:15163842</a>] </li><li id="reference-A11421">Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L: A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004 Sep 15;64(18):6652-9. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/15374980">PubMed:15374980</a>] </li><li id="reference-A11417">Grana TM, Sartor CI, Cox AD: Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance. Cancer Res. 2003 Nov 15;63(22):7807-14. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/14633707">PubMed:14633707</a>] </li><li id="reference-A11416">Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002 Sep 12;21(41):6255-63. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/12214266">PubMed:12214266</a>] </li><li id="reference-A11422">Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B, Menendez JA: Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. J Cell Physiol. 2011 Jan;226(1):52-7. doi: 10.1002/jcp.22333. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20658522">PubMed:20658522</a>] </li><li id="reference-A2252">Johnston SR, Leary A: Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc). 2006 Jul;42(7):441-53. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/16894399">PubMed:16894399</a>] </li><li id="reference-A2253">Tevaarwerk AJ, Kolesar JM: Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009;31 Pt 2:2332-48. doi: 10.1016/j.clinthera.2009.11.029. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20110044">PubMed:20110044</a>] </li><li id="reference-A2254">Medina PJ, Goodin S: Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18803986">PubMed:18803986</a>] </li><li id="reference-A9">Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/11752352">PubMed:11752352</a>] </li></ol></div></div></div></div></div><div class="bond-list-container enzymes"><h3 id="enzymes">Enzymes</h3><div class="bond-list"><div class="bond card" id="BE0002638"><div aria-hidden="true" aria-labelledby="binding properties" class="modal fade" id="BE0002638-binding-properties" role="dialog" tabindex="-1"><div class="modal-dialog modal-lg"><div class="modal-content"><div class="modal-header"><h5 class="modal-title">Binding Properties</h5><button aria-hidden="true" class="close" data-dismiss="modal" type="button">&times;</button></div><div class="modal-body"><div class="table-responsive"><table class="table table-sm"><thead><tr><th>Property</th><th>Measurement</th><th>pH</th><th>Temperature (°C)</th><th>References</th></tr></thead><tbody><tr><td>Ki (nM)</td><td>1700</td><td><span class='not-available'>N/A</span></td><td><span class='not-available'>N/A</span></td><td><span class="separated-list-container row"><span class="separated-list col-sm-6"><span class="separated-list-item"><a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/22409598">22409598</a></span></span></span></td></tr></tbody></table></div></div></div></div></div><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P08684"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#expand"> </use></svg></div> Details</a><button class="btn btn-sm btn-drugbank-secondary" data-target="#BE0002638-binding-properties" data-toggle="modal" type="button"><div class="drugbank-icon icon-details"><svg class="icon" role="img" title="details"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#details"> </use></svg></div> <span class='full-binding-label'>Binding Properties</a></button><strong>1. <a href="/polypeptides/P08684">Cytochrome P450 3A4</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Substrate</div><div class="badge badge-pill badge-action">Inhibitor</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6">General Function</dt><dd class="col-md-7 col-sm-6">Vitamin d3 25-hydroxylase activity</dd><dt class="col-md-5 col-sm-6">Specific Function</dt><dd class="col-md-7 col-sm-6">Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...</dd><dt class="col-md-5 col-sm-6">Gene Name</dt><dd class="col-md-7 col-sm-6">CYP3A4</dd><dt class="col-md-5 col-sm-6">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P08684">P08684</a></dd><dt class="col-md-5 col-sm-6">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Cytochrome P450 3A4</dd><dt class="col-md-5 col-sm-6">Molecular Weight</dt><dd class="col-md-7 col-sm-6">57342.67 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A2254">Medina PJ, Goodin S: Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18803986">PubMed:18803986</a>] </li><li id="reference-A14792">van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/19733976">PubMed:19733976</a>] </li><li id="reference-A15002">Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, Ho HK, Chan EC: Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703. doi: 10.1124/mol.110.065839. Epub 2010 Jul 12. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20624855">PubMed:20624855</a>] </li><li id="reference-L4141">Tykerb (Lapatinib) FDA Label [<a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf">Link</a>] </li></ol></div></div></div><div class="bond card" id="BE0002362"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P20815"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#expand"> </use></svg></div> Details</a><strong>2. <a href="/polypeptides/P20815">Cytochrome P450 3A5</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Substrate</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6">General Function</dt><dd class="col-md-7 col-sm-6">Oxygen binding</dd><dt class="col-md-5 col-sm-6">Specific Function</dt><dd class="col-md-7 col-sm-6">Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...</dd><dt class="col-md-5 col-sm-6">Gene Name</dt><dd class="col-md-7 col-sm-6">CYP3A5</dd><dt class="col-md-5 col-sm-6">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P20815">P20815</a></dd><dt class="col-md-5 col-sm-6">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Cytochrome P450 3A5</dd><dt class="col-md-5 col-sm-6">Molecular Weight</dt><dd class="col-md-7 col-sm-6">57108.065 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A2254">Medina PJ, Goodin S: Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18803986">PubMed:18803986</a>] </li><li id="reference-A14792">van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/19733976">PubMed:19733976</a>] </li><li id="reference-L4141">Tykerb (Lapatinib) FDA Label [<a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf">Link</a>] </li></ol></div></div></div><div class="bond card" id="BE0002887"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P10632"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#expand"> </use></svg></div> Details</a><strong>3. <a href="/polypeptides/P10632">Cytochrome P450 2C8</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Substrate</div><div class="badge badge-pill badge-action">Inhibitor</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6">General Function</dt><dd class="col-md-7 col-sm-6">Steroid hydroxylase activity</dd><dt class="col-md-5 col-sm-6">Specific Function</dt><dd class="col-md-7 col-sm-6">Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...</dd><dt class="col-md-5 col-sm-6">Gene Name</dt><dd class="col-md-7 col-sm-6">CYP2C8</dd><dt class="col-md-5 col-sm-6">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P10632">P10632</a></dd><dt class="col-md-5 col-sm-6">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Cytochrome P450 2C8</dd><dt class="col-md-5 col-sm-6">Molecular Weight</dt><dd class="col-md-7 col-sm-6">55824.275 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A15002">Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, Ho HK, Chan EC: Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703. doi: 10.1124/mol.110.065839. Epub 2010 Jul 12. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/20624855">PubMed:20624855</a>] </li><li id="reference-L2938">Get to know an Enzyme: CYP2C8 [<a target="_blank" href="http://www.hanstenandhorn.com/hh-article-December-2011.pdf">Link</a>] </li><li id="reference-L4141">Tykerb (Lapatinib) FDA Label [<a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf">Link</a>] </li><li id="reference-F132">EMA label, Lapatinib [<a target="_blank" href="//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/132/original/EMA_label.pdf?1528400667">File</a>] </li></ol></div></div></div><div class="bond card" id="BE0003536"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P33261"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#expand"> </use></svg></div> Details</a><strong>4. <a href="/polypeptides/P33261">Cytochrome P450 2C19</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Substrate</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6">General Function</dt><dd class="col-md-7 col-sm-6">Steroid hydroxylase activity</dd><dt class="col-md-5 col-sm-6">Specific Function</dt><dd class="col-md-7 col-sm-6">Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...</dd><dt class="col-md-5 col-sm-6">Gene Name</dt><dd class="col-md-7 col-sm-6">CYP2C19</dd><dt class="col-md-5 col-sm-6">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P33261">P33261</a></dd><dt class="col-md-5 col-sm-6">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Cytochrome P450 2C19</dd><dt class="col-md-5 col-sm-6">Molecular Weight</dt><dd class="col-md-7 col-sm-6">55930.545 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A2254">Medina PJ, Goodin S: Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18803986">PubMed:18803986</a>] </li><li id="reference-A14792">van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. doi: 10.1016/j.ctrv.2009.08.004. Epub 2009 Sep 5. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/19733976">PubMed:19733976</a>] </li><li id="reference-A38659">Nelson MH, Dolder CR: A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. Ther Clin Risk Manag. 2007 Aug;3(4):665-73. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18472989">PubMed:18472989</a>] </li><li id="reference-L4141">Tykerb (Lapatinib) FDA Label [<a target="_blank" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf">Link</a>] </li></ol></div></div></div></div></div><div class="bond-list-container transporters"><h3 id="transporters">Transporters</h3><div class="bond-list"><div class="bond card" id="BE0001032"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/P08183"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#expand"> </use></svg></div> Details</a><strong>1. <a href="/polypeptides/P08183">P-glycoprotein 1</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Inhibitor</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6">General Function</dt><dd class="col-md-7 col-sm-6">Xenobiotic-transporting atpase activity</dd><dt class="col-md-5 col-sm-6">Specific Function</dt><dd class="col-md-7 col-sm-6">Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.</dd><dt class="col-md-5 col-sm-6">Gene Name</dt><dd class="col-md-7 col-sm-6">ABCB1</dd><dt class="col-md-5 col-sm-6">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/P08183">P08183</a></dd><dt class="col-md-5 col-sm-6">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Multidrug resistance protein 1</dd><dt class="col-md-5 col-sm-6">Molecular Weight</dt><dd class="col-md-7 col-sm-6">141477.255 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A16202">Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW: Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008 Oct 1;68(19):7905-14. doi: 10.1158/0008-5472.CAN-08-0499. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18829547">PubMed:18829547</a>] </li><li id="reference-L2953">FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [<a target="_blank" href="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm">Link</a>] </li></ol></div></div></div><div class="bond card" id="BE0003109"><div class="card-header"><a class="btn btn-drugbank-secondary btn-sm bond-details-link ml-3" href="/polypeptides/Q03518"><div class="drugbank-icon icon-expand"><svg class="icon" role="img" title="expand"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#expand"> </use></svg></div> Details</a><strong>2. <a href="/polypeptides/Q03518">Antigen peptide transporter 1</a></strong></div><div class="card-body"><div class="row"><div class="col-sm-12 col-lg-5"><dl><dt class="col-md-5 col-sm-6">Kind</dt><dd class="col-md-7 col-sm-6">Protein</dd><dt class="col-md-5 col-sm-6">Organism</dt><dd class="col-md-7 col-sm-6">Humans</dd><dt class="col-md-5 col-sm-6">Pharmacological action</dt><dd class="col-md-7 col-sm-6"><div class="badge badge badge-unknown">Unknown</div></dd><dt class="col-md-5 col-sm-6">Actions</dt><dd class="col-md-7 col-sm-6"><div class="badge badge-pill badge-action">Inhibitor</div></dd></dl></div><div class="col-sm-12 col-lg-7"><dl><dt class="col-md-5 col-sm-6">General Function</dt><dd class="col-md-7 col-sm-6">Tap2 binding</dd><dt class="col-md-5 col-sm-6">Specific Function</dt><dd class="col-md-7 col-sm-6">Involved in the transport of antigens from the cytoplasm to the endoplasmic reticulum for association with MHC class I molecules. Also acts as a molecular scaffold for the final stage of MHC class ...</dd><dt class="col-md-5 col-sm-6">Gene Name</dt><dd class="col-md-7 col-sm-6">TAP1</dd><dt class="col-md-5 col-sm-6">Uniprot ID</dt><dd class="col-md-7 col-sm-6"><a target="_blank" rel="noopener" href="http://www.uniprot.org/uniprot/Q03518">Q03518</a></dd><dt class="col-md-5 col-sm-6">Uniprot Name</dt><dd class="col-md-7 col-sm-6">Antigen peptide transporter 1</dd><dt class="col-md-5 col-sm-6">Molecular Weight</dt><dd class="col-md-7 col-sm-6">87216.855 Da</dd></dl></div></div><h5>References</h5><div class="references"><ol class="cite-this-references"><li id="reference-A16202">Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW: Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008 Oct 1;68(19):7905-14. doi: 10.1158/0008-5472.CAN-08-0499. [<a target="_blank" rel="noopener" href="http://www.ncbi.nlm.nih.gov/pubmed/18829547">PubMed:18829547</a>] </li></ol></div></div></div></div></div><div aria-hidden="true" aria-labelledby="locked-modal-header" class="modal fade" id="locked-modal" role="dialog" tabindex="-1"><div class="modal-dialog modal-dialog-centered"><div class="modal-content"><div class="modal-body"><button aria-hidden="true" class="close" data-dismiss="modal" type="button">&times;</button><img src="/assets/unlock-molecule-f1ee80bcad8424455af34bbaf96169b955a5067b2c12914655e9e8596d175d1d.png" alt="Unlock molecule" /><div class="locked-modal-header"><div class="drugbank-icon icon-lock"><svg class="icon" role="img" title="lock"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#lock"> </use></svg></div>Unlock Data</div><p>There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.</p><a class="btn btn-sm btn-pink locked-modal-link track-link" target="_blank" href="https://drugbankplus.com/">Learn more</a></div></div></div></div><p class="bt-2" id="drug-meta">Drug created on May 16, 2007 11:27 / Updated on June 10, 2020 19:49 </p></div><div aria-hidden="true" aria-labelledby="package-image" class="modal fade" id="modal-package" role="dialog" tabindex="-1"><div class="modal-dialog"><div class="modal-content"><div class="modal-header"><h4 class="modal-title">Product Image</h4><button aria-hidden="true" class="close" data-dismiss="modal" type="button">&times;</button></div><div class="modal-body"><img class="img-thumbnail modal-package-picture mb-4" src="" /><a class="full-image float-right btn btn-drugbank-primary btn-sm mt-2" href="">Show full image</a><div class="package-description"></div></div></div></div></div><a target="_blank" id="targeted-ad" class="drugcard-ad track-link" href="https://drugbankplus.com/"><div class="targeted-ad-box"><div class="ad-button"><div class="expand-ad drugbank-icon icon-expand-ad"><svg class="icon" role="img" title="expand-ad"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#expand-ad"> </use></svg></div><div class="collapse-ad drugbank-icon icon-collapse-ad"><svg class="icon" role="img" title="collapse-ad"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#collapse-ad"> </use></svg></div></div><div class="ad-content"><div class="close-ad drugbank-icon icon-exit"><svg class="icon" role="img" title="exit"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#exit"> </use></svg></div><div class="image-row"><img height="15" src="/assets/logo-pink-bd7264e3b993f48d681445728e394507ac912eb6e426e52c6d3230a78dae4bc6.svg" alt="Logo pink" /></div><div class="text-row"><div class="title"><div class="lead">Are you a</div><div class="focus">new drug developer?</div></div><div class="subtitle"><div>Contact us to learn more about our customized products and solutions.</div></div></div></div></div></a><a target="_blank" id="targeted-image-ad" class="drugcard-ad track-link" href="https://drugbankplus.com/"><div class="targeted-ad-box targeted-image-box"><div class="ad-button"><div class="expand-ad drugbank-icon icon-expand-ad"><svg class="icon" role="img" title="expand-ad"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#expand-ad"> </use></svg></div><div class="collapse-ad drugbank-icon icon-collapse-ad"><svg class="icon" role="img" title="collapse-ad"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#collapse-ad"> </use></svg></div></div><div class="ad-content"><div class="close-ad drugbank-icon icon-exit"><svg class="icon" role="img" title="exit"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#exit"> </use></svg></div><img height="238" class="targeted-image" data-image-files="{&quot;CS-Molecular-Health-1.jpg&quot;:&quot;/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg&quot;,&quot;Drug-Dev-2.jpg&quot;:&quot;/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg&quot;,&quot;Drug-Search-3.jpg&quot;:&quot;/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg&quot;,&quot;PM-3.jpg&quot;:&quot;/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg&quot;,&quot;OD-Webinar-1.jpg&quot;:&quot;/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg&quot;,&quot;DDI-3.jpg&quot;:&quot;/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg&quot;,&quot;EMR-2.jpg&quot;:&quot;/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg&quot;,&quot;Covid.jpg&quot;:&quot;/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg&quot;}" src="" /></div></div></a><div class="drugcard-ad track-ad" id="social-ad"><div class="targeted-ad-box"><div class="ad-button"><div class="expand-ad drugbank-icon icon-expand-ad"><svg class="icon" role="img" title="expand-ad"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#expand-ad"> </use></svg></div><div class="collapse-ad drugbank-icon icon-collapse-ad"><svg class="icon" role="img" title="collapse-ad"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#collapse-ad"> </use></svg></div></div><div class="ad-content"><div class="close-ad drugbank-icon icon-exit"><svg class="icon" role="img" title="exit"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#exit"> </use></svg></div><div class="text-row"><div class="title"><img height="15" src="/assets/logo-pink-bd7264e3b993f48d681445728e394507ac912eb6e426e52c6d3230a78dae4bc6.svg" alt="Logo pink" /><div class="focus">Stay in the know!</div></div><div class="subtitle"><div>As part of our commitment to providing the most up-to-date drug information, we will be releasing <strong>#DrugBankUpdates</strong> with our newly added curated drug pages.</div></div></div><div class="icon-row"><a target="_blank" class="track-link" data-link-id="targeted/linkedin-1" href="https://www.linkedin.com/company/drugbank"><div class=" drugbank-icon icon-linkedin"><svg class="icon" role="img" title="linkedin"> <use xlink:href="/assets/plus/social_icons-d26022b9aaeed96dd6506eca605295fd0dcefdefe088cbaa55fd0e24291cf4b9.svg#linkedin"> </use></svg></div></a><a target="_blank" class="track-link" data-link-id="targeted/twitter-1" href="https://twitter.com/DrugBankDB"><div class=" drugbank-icon icon-twitter"><svg class="icon" role="img" title="twitter"> <use xlink:href="/assets/plus/social_icons-d26022b9aaeed96dd6506eca605295fd0dcefdefe088cbaa55fd0e24291cf4b9.svg#twitter"> </use></svg></div></a><a target="_blank" class="track-link" data-link-id="targeted/facebook-1" href="https://www.facebook.com/DrugBankDatabase/"><div class=" drugbank-icon icon-facebook"><svg class="icon" role="img" title="facebook"> <use xlink:href="/assets/plus/social_icons-d26022b9aaeed96dd6506eca605295fd0dcefdefe088cbaa55fd0e24291cf4b9.svg#facebook"> </use></svg></div></a><div class="hashtag">#DrugBankUpdates</div></div></div></div></div></div></main><footer class="p-3 p-sm-4"><div class="row"><div class="col-md-6 footer-links"><div class="container"><div class="row footer-row"><div class="col-md-4 footer-col"><div class="footer-header">About</div><div class="footer-list"><ul class="list-unstyled"><li><a href="/about">About DrugBank.ca</a></li><li><a target="_blank" href="https://blog.drugbankplus.com/">Blog</a></li><li><a target="_blank" href="http://www.wishartlab.com">Wishart Research Group</a></li><li><a href="https://drugbankplus.com/careers">Careers</a></li><li><a href="/legal/terms_of_use">Terms of Use</a></li><li><a href="/legal/privacy_policy">Privacy Policy</a></li></ul></div></div><div class="col-md-4 footer-col"><div class="footer-header">Support</div><div class="footer-list"><ul class="list-unstyled"><li><a target="_blank" href="https://dev.drugbankplus.com/guides/index">Help Center</a></li><li><a target="_blank" href="https://dev.drugbankplus.com/guides/faqs">DrugBank.ca FAQs</a></li><li><a href="/contact">Contact Support</a></li></ul></div></div><div class="col-md-4 footer-col"><div class="footer-header"><a href="https://drugbankplus.com/">Commercial Data</a></div><div class="footer-list"><ul class="list-unstyled"><li><a target="_blank" href="https://drugbankplus.com/clinical">Clinical Drug Data</a></li><li><a target="_blank" href="https://drugbankplus.com/scientific">Scientific Drug Data</a></li><li><a target="_blank" href="https://drugbankplus.com/contact/sales">Contact Sales</a></li></ul></div></div></div></div></div><div class="col-md-6 footer-support"><div class="social-media"><a class="social-media-link" href="https://www.facebook.com/DrugBankDatabase"><div class="drugbank-icon icon-facebook"><svg class="icon" role="img" title="facebook"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#facebook"> </use></svg></div></a><a class="social-media-link" href="https://twitter.com/DrugBankDB"><div class="drugbank-icon icon-twitter"><svg class="icon" role="img" title="twitter"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#twitter"> </use></svg></div></a><a class="social-media-link" href="mailto:support@drugbankplus.com"><div class="drugbank-icon icon-mail"><svg class="icon" role="img" title="mail"> <use xlink:href="/assets/icons-142218147183ad8ef70c8c6fc3f67dabdeb58443f11c0046485859cc16132882.svg#mail"> </use></svg></div></a></div><p class="funding">This project is supported by the <a href="http://www.cihr-irsc.gc.ca" target="_blank" rel="noopener">Canadian Institutes of Health Research</a> (award #111062), <a href="http://www.aihealthsolutions.ca" target="_blank" rel="noopener">Alberta Innovates - Health Solutions</a>, and by <a href="http://www.metabolomicscentre.ca/" target="_blank" rel="noopener">The Metabolomics Innovation Centre (TMIC)</a>, a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by <a href="http://www.genomealberta.ca" target="_blank" rel="noopener">Genome Alberta</a>, <a href="http://www.genomebc.ca/" target="_blank" rel="noopener">Genome British Columbia</a>, and <a href="http://www.genomecanada.ca" target="_blank" rel="noopener">Genome Canada</a>, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by <a href="http://omx.io">OMx Personal Health Analytics, Inc.</a> Designed by <a href="http://educedesign.com" target="_blank" rel="noopener">Educe Design & Innovation Inc.</a> </p><div class="logos d-flex justify-content-between flex-wrap"><div class="logo"><a target="_blank" rel="noopener" href="http://www.metabolomicscentre.ca"><img src="/assets/support/tmic-15c2cea3d7ba849188edb1dbed8dd9cb42cac3edf180a22a5a65e36692b2dc51.png" alt="Tmic" /></a></div><div class="logo"><a target="_blank" rel="noopener" href="http://www.cihr-irsc.gc.ca"><img src="/assets/support/cihr-a3aa20f1421f0fc32706170fcc96c55e298ecd74d5cfc3a0ef8999506d611f6e.png" alt="Cihr" /></a></div><div class="logo"><a target="_blank" rel="noopener" href="http://www.aihealthsolutions.ca"><img src="/assets/support/aihs-0c8d8ee9e0f7bb4a3e5a9ddaf953d7a211c7ee67d1c38f6df02a2478222d3bce.png" alt="Aihs" /></a></div><div class="logo"><a target="_blank" rel="noopener" href="http://genomealberta.ca"><img src="/assets/support/genome-alberta-3371e305e2a09ce9be32d5e6dfdcb28872c0131cd44209d6bb245b31a9ab2cef.png" alt="Genome alberta" /></a></div><div class="logo"><a target="_blank" rel="noopener" href="http://genomebc.ca"><img src="/assets/support/genome-bc-7a59f68b89b58ba1071569ab107d7618dc6a907865495f483152204804becf33.png" alt="Genome bc" /></a></div><div class="logo"><a target="_blank" rel="noopener" href="http://genomecanada.ca"><img src="/assets/support/genome-canada-4241484ec822ae236cfe26010d8de868dbf79c8f4554d888a516b390e14b9250.png" alt="Genome canada" /></a></div></div></div></div></footer><script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5a1c26f84a5f0712","version":"2020.5.1","si":10}'></script>
</body></html>